PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes

**HIGHLIGHTS**
- PRMT5 activates transcription of DSB repair genes upon DNA damage
- pICln cooperates with PRMT5 to activate transcription of DSB repair genes
- Targeting PRMT5 is effective to sensitize multiple cancer types to radiation
- PRMT5 expression positively correlates with DSB repair genes in cancer tissues

**DATA AND CODE AVAILABILITY**
GSE111620
PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes

Jake L. Owens,1 Elena Beketova,1,2,10 Sheng Liu,3,4,10 Samantha L. Tinsley,1,2 Andrew M. Asberry,1,2 Xuehong Deng,1 Jiaoti Huang,5 Chenglong Li,6 Jun Wan,3,4,7,8,* and Chang-Deng Hu1,9,11,*

SUMMARY
DNA double-strand break (DSB) repair is critical for cell survival and genome integrity. Upon recognition of DSBs, repair proteins are transiently upregulated to facilitate repair through homologous recombination (HR) or non-homologous end joining (NHEJ). We present evidence that PRMT5 cooperates with pICln to function as a master epigenetic activator of DNA damage response (DDR) genes involved in HR, NHEJ, and G2 arrest (including RAD51, BRCA1, and BRCA2) to upregulate gene expression upon DNA damage. Contrary to the predominant role of PRMT5 as an epigenetic repressor, our results demonstrate that PRMT5 and pICln can activate gene expression, potentially independent of PRMT5’s obligate cofactor MEP50. Targeting PRMT5 or pICln hinders repair of DSBs in multiple cancer cell lines, and both PRMT5 and pICln expression positively correlates with DDR genes across 32 clinical cancer datasets. Thus, targeting PRMT5 or pICln may be explored in combination with radiation or chemotherapy for cancer treatment.

INTRODUCTION
Repair of DNA double-strand breaks (DSBs), the most lethal DNA damage, is critical for cell survival and maintenance of genome integrity (Khanna and Jackson, 2001). DSBs can be induced both endogenously as well as exogenously through DNA damaging agents or ionizing radiation (IR). Upon recognition of extensive DSBs, repair proteins are upregulated (Khalil et al., 2012; Rieger, 2004; Russell et al., 2003) and recruited to the sites of damage to facilitate repair through either homologous recombination (HR) or non-homologous end joining (NHEJ) (Thompson, 2012). Although the highly regulated recruitment and action of repair proteins are well characterized, little is known about how their expression is induced upon DNA damage.

Protein arginine methyltransferase 5 (PRMT5) is an emerging epigenetic enzyme that regulates cellular processes including cell proliferation, differentiation, and cell cycle progression (Karkhanis et al., 2011; Stopa et al., 2015). PRMT5 regulates these cellular processes through changes in gene expression via symmetrical dimethylation of arginine residues in histones H4R3 (H4R3me2s), H3R2 (H3R2me2s), H3R8 (H3R8me2s), and H2AR3 (H2AR3me2s) and post-translational regulation of non-histone substrates (Stopa et al., 2015). PRMT5 activity is modulated by several interacting proteins including MEP50, which is believed to be the obligate cofactor of PRMT5 and required for PRMT5 methyltransferase activity (Burgos et al., 2015; Chen et al., 2017; Karkhanis et al., 2011; Stopa et al., 2015). Accumulating evidence suggests that PRMT5 may act as an oncogene to promote cancer cell growth (Karkhanis et al., 2011; Stopa et al., 2015). Consistent with this, PRMT5 is overexpressed in several cancers and its elevated expression correlates with disease progression and poor prognosis (Karkhanis et al., 2011; Stopa et al., 2015; Yang and Bedford, 2013). Thus, PRMT5 has been proposed as a potential therapeutic target for cancer treatment (Richters, 2017).

We have recently reported that PRMT5 is overexpressed in ~60% of intermediate- and high-risk prostate cancer cases and that PRMT5 expression in prostate cancer tissues positively correlates with androgen receptor (AR) expression (Deng et al., 2017). Mechanistically, PRMT5 is recruited to the AR promoter to activate AR transcription through H4R3me2s in prostate cancer cells (Deng et al., 2017). Because AR drives prostate cancer development and progression, targeting AR signaling through androgen deprivation therapy (ADT) is a standard of care to treat metastatic prostate cancer (Heidenreich et al., 2014). ADT is also...
used as a radiosensitization approach to enhance radiation therapy (RT) for localized prostate cancer patients (Golabek et al., 2016). Our finding that PRMT5 activates AR transcription raised the possibility that PRMT5 may be a therapeutic target for prostate cancer radiosensitization.

Contrary to our expectation, we observed that targeting PRMT5 sensitized prostate cancer cells to IR independently of AR expression. Here, we present evidence that PRMT5 cooperates with pICln, independently of its canonical cofactor MEP50, to function as a master epigenetic activator of DNA damage response (DDR) genes in various cell types. Upon DNA damage, PRMT5 and pICln upregulate target genes that encode proteins involved in HR (RAD51, RAD51D, RAD51AP1, BRCA1, and BRCA2), NHEJ (NHEJ1/XLF and DNAPKcs), and G2 arrest (WEE1). Targeting PRMT5 or pICln decreases expression of these DDR genes and hinders repair of DSBs in multiple cancer cell lines suggesting that PRMT5 may play a conserved role in DDR. Thus, targeting PRMT5 or pICln may be explored as a monotherapy or in combination with radiation or chemotherapy for cancer treatment. Significantly, both PRMT5 and pICln expression positively correlates with the expression of these target genes across most of the 32 clinical cancer datasets analyzed. Although PRMT5, along with its obligate cofactor MEP50, primarily functions as an epigenetic repressor, our results demonstrate that PRMT5 together with pICln can activate gene expression and provide a potential mechanism for the transient upregulation of repair proteins upon DNA damage.

RESULTS
Targeting PRMT5 Sensitizes Prostate Cancer Cells to IR in an AR-Independent Manner
ADT is the only approved clinical radiosensitization approach for prostate cancer treatment (Golabek et al., 2016). Because we recently identified PRMT5 as a novel epigenetic activator of AR (Deng et al., 2017), we tested whether targeting PRMT5 can mimic ADT to sensitize prostate cancer cells to IR. To this end, we established lentivirally infected stable pools with doxycycline (Dox)-inducible PRMT5 knockdown and observed that knockdown of PRMT5 sensitized AR-expressing LNCaP prostate cancer cells (LNCaP-shPRMT5 pool) to IR when compared with scramble control cell lines (LNCaP-shSC) (Figure 1A). Likewise, inhibition of PRMT5 by our inhibitor BLL3.3 (Alinari et al., 2015; Deng et al., 2017) also sensitized LNCaP cells to IR (Figure 1B). Consistent with previous findings that AR regulates several target genes involved in NHEJ (Goodwin et al., 2013; Polkinghorn et al., 2013; Tarish et al., 2015), pharmacological inhibition of PRMT5 with BLL3.3 in irradiated LNCaP cells indeed caused a decrease in AR expression and a concomitant decrease in the expression of Ku80/XRCC5, XRCC4, and DNAPKcs/PRKDC at the mRNA level (Figure 1C). Contrary to our expectation, knockdown of PRMT5 also sensitized AR-negative prostate cancer cell lines PC3 and DU145 to IR when similar Dox-inducible knockdown stable cell lines (PC3-shPRMT5 pool and DU145-shPRMT5 pool) were used (Figures 1D and 1E). However, BLL3.3 treatment had little to no effect on the expression of AR-target genes involved in NHEJ in irradiated AR-negative DU145 cells (Figure 1F). Given these results, we isolated single-cell-derived clones to develop Dox-inducible knockdown stable cell lines (LNCaP-shPRMT5 and LNCaP-shPRMT5 #2) for all subsequent studies. Dox-induced PRMT5 knockdown is shown in Figures S3B–S3F and is reported previously (Deng et al., 2017). These results suggest that the radiosensitization effect of PRMT5 targeting in prostate cancer cells is likely mediated through both AR-dependent and -independent mechanisms.

PRMT5 Regulates the Repair of DNA Double-Strand Breaks in Prostate Cancer Cells Independently of AR Expression
Next, we determined if the radiosensitization effect of PRMT5 targeting was due to defects in the repair of IR-induced DSBs. We first treated LNCaP cells with IR and quantified DSBs via γH2AX foci analysis to assess the formation and repair of IR-induced DSBs. The majority of DSBs were repaired within 2–6 h following IR treatment (Figures 2A and 2B). To assess if PRMT5 is required for efficient repair of IR-induced DSBs, we analyzed γH2AX foci 6 h following IR in more detail. Cells with PRMT5 knockdown retained significantly more DSBs 6 h following IR treatment than cells without knockdown, indicating a defect in DSB repair (Figures 2C and 2D). Nearly identical results were obtained using a different PRMT5-targeting shRNA (LNCaP-shPRMT5 #2) (Figures 2E and 2F). Treatment of LNCaP cells with BLL3.3 conferred the same effect as PRMT5 knockdown (Figures 2G and 2H), whereas Dox-induced expression of scramble control (SC) shRNA in LNCaP-shSC cells had no effect (Figures 2I and 2J). Cells with PRMT5 knockdown retained significantly more γH2AX foci even 24 h following IR treatment than cells without knockdown (Figures 2K and 2L), indicating a prolonged defect in DSB repair. The defects in DSB repair upon PRMT5 knockdown were unlikely an artifact of crosstalk between histone posttranslational modifications, as we observed similar results when quantifying DNA damage directly via comet assay (Figures S1A–S1D). Furthermore, knockdown of
PRMT5 also hinders repair of etoposide-induced DSBs (Figures S2A and S2B), which differ in their mechanism of DSB generation and are replication dependent (Furuta et al., 2003; Montecucco and Biamonti, 2007; Treszezamsky et al., 2007), suggesting that PRMT5 may be required for repair of DSBs independently of how they are formed. Thus, the radiosensitization effect of PRMT5 targeting in prostate cancer cells is likely due to defects in the repair of IR-induced DSBs.

To further confirm that PRMT5 also regulates the repair of IR-induced DSBs independently of AR, we performed rescue experiments. Although exogenously expressed AR in Dox-treated LNCaP-shPRMT5 cells fully rescued AR protein levels (Figures 2M and 2N), the repair of IR-induced DSBs was only partially rescued (Figures 2O and 2P). Thus, PRMT5 can also regulate repair of IR-induced DSBs through an AR-independent mechanism.

PRMT5 Regulates NHEJ, HR, and G2 Arrest in Response to IR

The ability to repair DSBs is mainly dependent on NHEJ and HR as well as G1 and G2 cell-cycle arrest. We next analyzed IR-induced Ku70 and RAD51 foci formation to examine if PRMT5 knockdown would affect NHEJ or HR repair, respectively. Consistent with the finding that targeting PRMT5 causes a decrease in AR-target genes involved in NHEJ, PRMT5 knockdown decreased IR-induced Ku70 foci formation (Figures 3A and 3B), indicating that PRMT5 regulates NHEJ. Interestingly, PRMT5 knockdown also decreased IR-induced RAD51 foci formation (Figures 3C and 3D), confirming that PRMT5 regulates HR repair of IR-induced DSBs as well.

To further investigate whether PRMT5 knockdown has any effect on cell cycle. Consistent with previous findings (Lim et al., 2014; Scoumanne et al., 2009; Wei et al., 2012; Yang et al., 2016), cells with PRMT5...
Figure 2. PRMT5 Regulates the Repair of DNA Double-Strand Breaks in Prostate Cancer Cells Independently of AR Expression
(A) Time course of the formation and repair of DSBs (γH2AX foci) at the indicated minutes (m) or hours (h) post 2 Gy IR in LNCaP cells. (B) Quantification of DSBs in each individual cell from A: “average” indicates the average number of DSBs in each cell and “0 foci” indicates the percentage of cells that do not contain any DSBs. (C, E, G, I, and K) DSBs 6 h or 24 h post 2 Gy IR in the indicated cells (C: LNCaP-shPRMT5, E: LNCaP-shPRMT5 #2, G: LNCaP, I: LNCaP-shSC, K: LNCaP-shPRMT5) with (Dox+) and without (Dox–) PRMT5 knockdown/scramble control (SC) knockdown or with (BLL3.3) and without (DMSO) PRMT5 inhibition. (D, H, J, and L) Quantification of DSBs from C, E, G, I, and K as described above in Figure 2B (C: LNCaP-shPRMT5, E: LNCaP-shPRMT5 #2, G: LNCaP, I: LNCaP-shSC, K: LNCaP-shPRMT5).
knockdown had an increase in the G1 population and a concomitant decrease in the S population in the absence of IR (Figure 3E) indicative of G1 arrest. Upon IR treatment, cells with PRMT5 knockdown retained the ability to undergo IR-induced G1 arrest (or already arrested in G1 phase due to PRMT5 knockdown prior to IR) yet failed to arrest at G2 (Figure 3F). This result suggests that PRMT5 regulates IR-induced G2 arrest but may not be required for IR-induced G1 arrest. Overall, our findings that PRMT5 can regulate repair of IR-induced DSBs through an AR-independent mechanism and that targeting PRMT5 sensitizes prostate cancer cells to IR independently of AR expression are likely due to the regulation of multiple DDR pathways by PRMT5.

Because PRMT5 is an emerging epigenetic regulator (Karkhanis et al., 2011; Stopa et al., 2015), we reasoned that PRMT5 may regulate the expression of genes involved in the repair of DSBs. We performed RNA-seq analysis of both non-irradiated (IR-) and irradiated (IR+) LNCaP-shPRMT5 cells with PRMT5 knockdown (Dox+) and without PRMT5 knockdown (Dox-). We identified 2,036 differentially expressed RNA-seq analysis of both non-irradiated (IR-) and irradiated (IR+) LNCaP-shPRMT5 cells with PRMT5 knockdown had an increase in the G1 population and a concomitant decrease in the S population in the absence of IR (Figure 3E) indicative of G1 arrest. Upon IR treatment, cells with PRMT5 knockdown retained the ability to undergo IR-induced G1 arrest (or already arrested in G1 phase due to PRMT5 knockdown prior to IR) yet failed to arrest at G2 (Figure 3F). This result suggests that PRMT5 regulates IR-induced G2 arrest but may not be required for IR-induced G1 arrest. Overall, our findings that PRMT5 can regulate repair of IR-induced DSBs through an AR-independent mechanism and that targeting PRMT5 sensitizes prostate cancer cells to IR independently of AR expression are likely due to the regulation of multiple DDR pathways by PRMT5.

PRMT5 Activates Transcription of Genes that Encode Proteins Involved in the Repair of DSBs

Next, we sought to validate a potential role for PRMT5 in regulating the transcription of genes required for DSB repair. Notably, we identified six DEGs that encode repair proteins (RAD51, RAD51D, RAD51AP1, BRCA1, BRCA2, and NHEJ1/XLF), and the regulation of these genes by PRMT5 in both irradiated and non-irradiated cells was verified by reverse transcriptase quantitative real-time PCR (RT-qPCR) (Figures 4A and S3A) and Western blot (Figures S3B–S3F) (additional genes were also individually verified at the mRNA level in Figure S3G). IR induces the expression of these genes at both the mRNA (Figure 4B) and protein level (Figures S3B–S3F) on a timescale consistent with the repair of IR-induced DSBs, suggesting that PRMT5-mediated upregulation of these genes upon IR is critical for DSB repair. The regulation of positive control genes by PRMT5 was also confirmed: knockdown of PRMT5 prevented repression of IVL expression (Saha et al., 2016) and prevented activation of AR expression (Deng et al., 2017) (Figures 4A and S3G). As expected, IR did not affect expression of IVL or AR at the mRNA level (data not shown).

Chromatin immunoprecipitation (ChIP)-qPCR assays using LNCaP-shSC and LNCaP-shPRMT5 cell lines confirmed that PRMT5 indeed bound to the proximal promoter regions of these six genes that encode
Figure 3. PRMT5 Regulates NHEJ, HR, and G2 Arrest in Response to IR

(A) NHEJ repair foci (Ku70) 1 h post 2 Gy IR in LNCaP-shPRMT5 cells with (Dox+) and without (Dox−) PRMT5 knockdown.
(B) Quantification of Ku70 foci from A as described in Figure 2 B.
(C) HR repair foci (RAD51) 1 h post 2 Gy IR in LNCaP-shPRMT5 cells with (Dox+) and without (Dox−) PRMT5 knockdown.
(D) Quantification of RAD51 foci from C as described in Figure 2 B.
(E) Cell-cycle analysis via flow cytometry of propidium iodide (PI) stained LNCaP-shPRMT5 cells with (Dox+) and without (Dox−) PRMT5 knockdown.
(F) Cell cycle analysis via flow cytometry of PI-stained LNCaP-shPRMT5 cells 24 h post 2 Gy IR, with (Dox+) and without (Dox−) PRMT5 knockdown.
(G) RNA-seq analysis 1 h post 2 Gy IR in irradiated (IR+) and non-irradiated (IR−) LNCaP-shPRMT5 cells with (Dox+) and without (Dox−) PRMT5 knockdown. Volcano plot shows statistical significance (false discovery rate, FDR-corrected p values) vs fold change (FC, in logarithm scale with base 2) between PRMT5 knockdown and WT in IR+ and IR− cells, respectively. Upregulated DEGs (red or green) and downregulated DEGs (blue or yellow) are indicated in color.
(H) Venn diagram indicating the overlap of DEGs between IR+ (red or blue) and IR− (green or yellow) samples.
(I) Gene ontology (GO) analysis of IR+ only DEGs that were downregulated upon PRMT5 knockdown. Groups of GO terms related to DNA repair and cell-cycle regulation were identified to be significantly enriched in the DEG set. The height of each bar represents the enrichment score for the GO term, whereas the q-value (FDR-corrected p value) in red indicates the significance of enrichment. The number in the bar indicates the number of DEGs associated with the corresponding GO annotation.
Since CCNB2, CDC20, CDC25C, and CDK1 are typically activators of G2 progression and WEE1 is an activator of G2/M transition (DEGs: CCNB2, CDC20, CDC25C, CDK1, and WEE1), the net phenotypic effect is impaired IR-induced G2 arrest. Knockdown of MEP50 caused an increase in IVL expression (Figure 5A). Furthermore, MEP50 knockdown plays a role in regulating the expression of DDR genes. Using Dox-inducible MEP50 knockdown stable cell lines isolated from single-cell-derived clones (LNCaP-shMEP50), we unexpectedly observed that knockdown of MEP50 did not affect the expression of PRMT5 target genes involved in DDR at the mRNA level upon PRMT5 knockdown, the net phenotypic effect is impaired IR-induced G2 arrest.

**pICln Is Also Required for Transcriptional Activation of DDR Genes and for Efficient Repair of DSBs**

As MEP50 is believed to be the obligate cofactor of PRMT5 and required for PRMT5 methyltransferase activity (Stopa et al., 2015; Wilczek et al., 2011; Chen et al., 2017; Burgos et al., 2015), we determined if MEP50 plays a role in regulating the expression of DDR genes. Using Dox-inducible MEP50 knockdown stable cell lines isolated from single-cell-derived clones (LNCaP-shMEP50), we unexpectedly observed that knockdown of MEP50 did not affect the expression of PRMT5 target genes involved in DDR at the mRNA (Figure 5A) or protein (Figures S5A and S5B) level in untreated or irradiated LNCaP-shMEP50 cells. However, consistent with the previous finding that PRMT5 and MEP50 represses IVL expression (Saha et al., 2016), knockdown of MEP50 caused an increase in IVL expression (Figure 5A). Furthermore, MEP50 knockdown did not affect the repair of IR-induced DSBs (Figures 5B and 5C). These results suggest that PRMT5 may not rely on MEP50 to regulate transcription of genes involved in DDR.

We previously performed mass spectrometry analysis of PRMT5-immunoprecipitated lysate to identify interacting proteins of PRMT5 in LNCaP cells (Zhang et al., 2016). We predictably identified MEP50 (peptide fragment GLGTGTLYIAESR), but we also identified pICln (Chari et al., 2008; Friessen et al., 2001, 2002; Guderian et al., 2011; Meister et al., 2001) (peptide fragment GLGTG7LY/AESR) as an interacting protein of PRMT5. We then developed Dox-inducible pICln knockdown stable cell lines isolated from single-cell-derived clones (LNCaP-shpICln) and surprisingly observed that knockdown of pICln caused a decrease in PRMT5 target gene expression at the mRNA (Figure 5D) and protein (Figures S5C and S5D) level in untreated and irradiated LNCaP-shpICln cells. Furthermore, knockdown of pICln impaired repair of IR-induced DSBs (Figures 5E and 5F) to an extent comparable to PRMT5 knockdown. Although MEP50 was present at the promoter of the control gene IVL, MEP50 was not present at the promoter of PRMT5 target genes involved in DDR.

**Figure 3. Continued**

(J) Differentially regulated pathways of IR+ only DEGs that were downregulated upon PRMT5 knockdown identified by IPA. The pathways with the highest –log (p value), represented by the bars, are shown. Pathways shown in blue (negative Z score) are inhibited upon PRMT5 knockdown, whereas pathways in orange (positive Z score) are activated upon PRMT5 knockdown.

Fluorescence images in A and C are representative immunocytochemistry images (blue = DAPI, green = Ku70, red = RAD51). Bars in B and D are the mean ± s.d. of three independent experiments, whereas bars in E and F are the mean ± s.d. of four independent experiments. Graphs in E and F are representative flow traces of cells in various cell-cycle stages (green = G1, orange = S, blue = G2). Statistical analysis comparing experimental with the control ("Dox–") was performed using Welch’s t test (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, NS p > 0.05).
genes involved in DDR while pICln was present (Figures S5G, S5H, S5E, and S5F). Upon IR, binding of pICln to the promoter of DDR genes increased (Figure S5H) and knockdown of PRMT5 almost completely abrogated enrichment of pICln (Figure S5F), suggesting that PRMT5 recruits pICln to targeted promoter regions. Additionally, other previously identified PRMT5 interacting proteins, RioK1 (Guderian et al., 2011) and COPR5 (Lacroix et al., 2008; Paul et al., 2012, 2015), were not found at the promoter of DDR genes in
Figure 5. pICln is Also Required for Transcriptional Activation of DDR Genes and for Efficient Repair of DSBs

(A) Quantification of mRNA via RT-qPCR 2 h post 2 Gy IR in LNCaP-shMEP50 cells with (Dox+) and without (Dox−) MEP50 knockdown. For each biological replicate, values were normalized to the value for "Dox−, IR−" (untreated) to calculate the fold change in mRNA expression upon treatment.

(B) DSBs 6 h post 2 Gy IR in LNCaP-shMEP50 cells with (Dox+) and without (Dox−) MEP50 knockdown.

(C) Quantification of DSBs in each individual cell from B as described in Figure 2B.

(D) Quantification of mRNA via RT-qPCR 2 h post 2 Gy IR in LNCaP-shpICln cells with (Dox+) and without (Dox−) pICln knockdown. For each biological replicate, values were normalized to the value for "Dox−, IR−" (untreated) to calculate the fold change in mRNA expression upon treatment.

(E) DSBs 6 h post 2 Gy IR in LNCaP-shpICln cells with (Dox+) and without (Dox−) pICln knockdown.

(F) Quantification of DSBs in each individual cell from E as described in Figure 2B.

(G and H) Quantification of enrichment (G: MEP50 and H: pICln) at the promoter region of the indicated genes 1 h post 2 Gy IR via ChIP-qPCR in irradiated (IR+) and non-irradiated (IR−) LNCaP-shSC cells via ChIP-qPCR. For each biological replicate, the value for IP was normalized to the value for IgG to calculate the fold enrichment (see also Figures S5E and S5F).

Fluorescence images in B and E are representative immunocytochemistry images (blue = DAPI, green = γH2AX, red = MEP50 or pICln). All bars are the mean ± s.d. of three independent experiments. Statistical analysis for A and D comparing experimental with the control ("Dox−, IR−") was performed using Brown-Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test, whereas statistical analysis for C, F, G, and H comparing experimental with the control ("Dox−" or "IgG") was performed using Welch’s t test (*p ≤ 0.05; **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, NS p > 0.05).
**Fold change upon IR treatment (intensity)**

- **PRMT5**
  - IR- 5 m 1 h 2 h 6 h 24 h
  - 1.00 2.08 2.35 1.55 1.44 0.07

- **γH2AX**
  - IR- 5 m 1 h 2 h 6 h 24 h
  - 1.00 4.27 3.43 2.10 1.68 1.06

- **β-Actin**
  - IR- 5 m 1 h 2 h 6 h 24 h
  - 1.00 1.14 1.44 1.33 0.94 0.91

**Fold change upon IR treatment (mRNA)**

- **PRMT5**
  - IR- 5 m 1 h 2 h 6 h 24 h
  - 1.00 4.27 3.43 2.10 1.68 1.06

**Fold change upon IR treatment (protein)**

- **Whole cell**
  - Nuclear Cytoplasmic N:C Ratio
  - 50 μm

- **Cytoplasmic**
  - Nuclear (MEP50 intensity)
  - 50 μm

- **Cytoplasmic**
  - Nuclear (pICln intensity)
  - 50 μm

**Fold change upon IR treatment (MEP50 intensity)**

- **Whole cell**
  - Nuclear Cytoplasmic N:C Ratio
  - 50 μm

- **Cytoplasmic**
  - Nuclear (MEP50 intensity)
  - 50 μm

- **Cytoplasmic**
  - Nuclear (pICln intensity)
  - 50 μm

**Fold change upon IR treatment (pICln intensity)**

- **Whole cell**
  - Nuclear Cytoplasmic N:C Ratio
  - 50 μm

- **Cytoplasmic**
  - Nuclear (MEP50 intensity)
  - 50 μm

- **Cytoplasmic**
  - Nuclear (pICln intensity)
  - 50 μm

**Fold change upon IR treatment (BiFC intensity)**

- **Whole cell**
  - Nuclear Cytoplasmic N:C Ratio
  - 50 μm

- **Cytoplasmic**
  - Nuclear (MEP50 intensity)
  - 50 μm

- **Cytoplasmic**
  - Nuclear (pICln intensity)
  - 50 μm
Figure 6. IR Induces PRMT5 Expression, pICln Nuclear Localization, and the PRMT5:pICln Interaction in the Nucleus

(A) Time course of PRMT5 expression at the indicated minutes (m) or hours (h) post 2 Gy IR in LNCaP cells. For each biological replicate, values were normalized to the value for “IR–” to calculate the fold change in protein expression upon IR.

(B) Quantification of PRMT5 expression in images from A. For each biological replicate used as the representative Western blot.

(C) Representative Western blot showing the time course of protein expression at the indicated minutes (m) or hours (h) post 2 Gy IR in LNCaP cells. Values were normalized to the value for “IR–” to calculate the fold change in protein expression upon IR.

(D) Quantification of protein expression via Western blotting from C. For each biological replicate, values were normalized to the value for “IR–” to calculate the fold change in protein expression upon IR.

(E) Time course of PRMT5 expression at the mRNA level at the indicated minutes (m) or hours (h) post 2 Gy IR in LNCaP cells via RT-qPCR. For each biological replicate, values were normalized to the value for “IR–” to calculate the fold change in mRNA expression upon IR.

(F) Time course of MEP50/pICln expression/localization at the indicated minutes (m) or hours (h) post 2 Gy IR in LNCaP cells. Values were normalized to the value for “IR–” to calculate the fold change in mRNA expression upon IR.

(G) Quantification of MEP50 expression/localization in images from F. “Whole cell” indicates MEP50 expression in the entire cell, “Nuclear” indicates MEP50 expression in the nucleus, which was defined by DAPI staining, “Cytoplasmic” indicates MEP50 expression in the cytoplasm that was defined as staining outside DAPI, and “N:C ratio” was calculated by dividing the value for nucleus by the value for cytoplasmic for each cell individually such that an N:C ratio of 1 indicates equal expression in both the nucleus and cytoplasm.

(H) Quantification of pICln expression/localization in images from F as described above.

(I) PRMT5:MEP50 and PRMT5:pICln interaction 6 h post 2 Gy IR in irradiated (IR–) and non-irradiated (IR+) LNCaP cells via BiFC assay.

(J) Quantification of PRMT5:MEP50 BiFC intensity in images from I. “Whole cell” indicates BiFC intensity in the entire cell, “Nuclear” indicates BiFC intensity in the nucleus that was defined by NLS-CFP signal, “Cytoplasmic” indicates BiFC intensity in the cytoplasm that was defined as staining outside NLS-CFP signal, and “N:C ratio” was calculated by dividing the value for nucleus by the value for cytoplasmic for each cell individually such that an N:C ratio of 1 indicates equal interaction in both the nucleus and cytoplasm. NLS-CFP was used as a transfection control and a marker of the nucleus.

(K) Quantification of PRMT5:pICln BiFC intensity in images from I as described above.

Fluorescence images in A are representative immunocytochemistry images (red = PRMT5). Fluorescence images in F are representative immunocytochemistry images (red = DAPI and red = MEP50 or pICln). Blue circles outline DAPI staining to allow for better visibility of expression in the nucleus. Fluorescence images in I are representative images from BiFC assay (green = PRMT5:MEP50 and PRMT5:pICln, cerulean = NLS-CFP). Blue circles outline NLS-CFP signal to allow for better visibility of expression in the nucleus. All bars are the mean ± s.d. of three independent experiments. Statistical analysis for B, D, E, G, and H was performed using the Brown-Forsythe test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001, NS p > 0.05).

IR Induces PRMT5 Expression, pICln Nuclear Localization, and the PRMT5:pICln Interaction in the Nucleus

Given the importance of PRMT5 in DSB repair and activation of target gene expression upon IR, we hypothesized that IR may induce PRMT5 expression. To test this, we analyzed PRMT5 protein expression via both immunocytochemistry and Western blotting at various time points following IR of LNCaP cells. Indeed, IR induced PRMT5 expression as quickly as 5 m, and the induction lasted for nearly 24 h (Figures 6A–6D). Importantly, the peak of PRMT5 protein expression (between 5 m and 1 h) coincided with the increased recruitment of PRMT5 to the promoters of DDR genes (1 h). Similarly, changes in PRMT5 expression closely mirrored the time course of DSB repair. The rapid induction of protein expression likely suggests a post-transcriptional or post-translational regulation. However, RT-qPCR analysis confirmed a small, but significant, sustained induction of PRMT5 expression at the mRNA level (Figure 6E). This result suggests that transcriptional activation of PRMT5 also contributes to prolonged elevation of PRMT5 expression. Furthermore, PRMT5 was upregulated at the protein level by etoposide treatment (Figures S2C–S2F), suggesting that DNA damage, in general, can signal the induction of PRMT5. Collectively, these results indicate that PRMT5 is upregulated upon IR to promote repair of IR-induced DSBs, and that the upregulation of DDR genes is likely facilitated by IR-induced upregulation of PRMT5.

To gain insight into how pICln functions with PRMT5 to regulate the expression of genes involved in DDR, we first determined if IR affects expression of MEP50 or pICln. However, neither MEP50 nor pICln protein expression was affected by IR (Figures 6F–6H). We next analyzed the subcellular localization of MEP50 and pICln upon IR. Upon IR, the nuclear:cytoplasmic (N:C) ratio of MEP50 decreased, whereas the N:C ratio of pICln increased (Figures 6F–6H). This suggests that upon IR there is more pICln and less MEP50 in the nucleus to interact with PRMT5. IR-induced nuclear localization of pICln thus likely contributes to IR-induced pICln binding to the promoters of genes involved in DDR. To assess the protein-protein interaction (PPI) directly, we utilized bimolecular fluorescence complementation (BiFC) assay (Hu et al., 2002; Kodama and Hu, 2010, 2012; Shyu and Hu, 2008), which is uniquely applicable in assessing the subcellular...
Figure 7. PRMT5 Regulates the Expression of DDR Genes in Multiple Cancer Cell Lines, and PRMT5 Expression Positively Correlates with DDR Genes in Human Cancer Tissues

(A) Quantification of DSBs 6 h post 2 Gy IR in the indicated cell lines with (BLL3.3) and without (DMSO) PRMT5 inhibition as described in Figure 2B (see also Figures S7A—S7E for representative images).

(B) Quantification of mRNA via RT-qPCR 6 h post 2 Gy IR in the indicated cell lines with (BLL3.3) and without (DMSO) PRMT5 inhibition. For each biological replicate, values were normalized to the value for “DMSO/IR/C0” (untreated) to calculate the fold change in mRNA expression upon treatment (see also Figures S7F—S7J for statistical analysis).

(C) Violin plots representing Spearman correlations comparing the mRNA expression level between PRMT5 and DDR genes (DDR), PRMT5 and AR (AR), or PRMT5 and all other genes (All other) across 32 clinical cancer datasets from TCGA. The gene set for DDR genes was defined as RAD51, RAD51D, RAD51AP1, NHEJ1, BRCA1, BRCA2, WEE1, DNAPKcs, Ku70, Ku80, and XRCC4 (see also Figure S8).

(D) Violin plots representing Spearman correlations comparing the mRNA expression level between DDR genes and PRMT5. Cancer types were stratified by the correlation coefficient (c.c.) between PRMT5 and AR: positively correlated (c.c. > 0 & p < 0.01) (Positive), negatively correlated (c.c. < 0 & p < 0.01) (Negative), or not correlated (p > 0.01) (Non).

(E) Violin plot representation of Spearman correlation values between DDR genes and either PRMT5, CLNS1A (pICln), or WDR77 (MEP50).
BiFC confirmed an IR-induced PPI increase between PRMT5 and pICln and a decrease in the PRMT5:MEP50 PPI, particularly in the nucleus (Figures 6I–6K). Overall, these results suggest that the regulation of genes involved in DDR by PRMT5 is facilitated by the IR-induced PRMT5:pICln interaction in the nucleus.

The Transcriptional Regulation of DSB Repair Genes by PRMT5 Is Not Dependent on RuvBL1 or Tip60

While this study was ongoing, Clarke et al reported that PRMT5 participates in the DSB repair choice process and promotes HR through methylation of RuvBL1: Methylation of RuvBL1 by PRMT5 alters the RuvBL1:Tip60 complex, promotes Tip60-mediated acetylation of histone H4K16, demotes 53BP1 binding to DSBs, and initiates DSB repair via HR (Clarke et al., 2017). We sought to confirm that the mechanism we describe here is independent of RuvBL1 and Tip60. We determined that knockdown of RuvBL1 did not affect expression of PRMT5, RAD51, RAD51D, RAD51AP1, NHEJ1, and Tip60 at the protein level (Figures S6A and S6B), nor did it affect the efficiency of repair of IR-induced DSBs in LNCaP cells (Figures S6C and S6D). This is consistent with another study reporting that knockdown of RuvBL1 had no effect on IR-induced 53BP1 foci in hematopoietic cells (Hamard et al., 2018). Therefore, methylation of RuvBL1 by PRMT5 likely affects DSB repair choice (favoring HR over NHEJ) but not the overall efficiency of repair, whereas the transcriptional activation of DDR genes by PRMT5 is likely required for repair of DSBs.

Similarly, while this study was ongoing, Hamard et al. also reported that PRMT5 regulates DSB repair choice via splicing of Tip60 in hematopoietic cells: PRMT5 is required for appropriate splicing of Tip60, which in turn allows for normal Tip60 acetyltransferase activity, demotes 53BP1 binding to DSBs, and initiates DSB repair via HR (Hamard et al., 2018). Knockdown of Tip60 did not affect the expression of PRMT5 or the putative PRMT5 target genes we characterized (Figures S6E and S6F), suggesting that PRMT5-associated splicing of Tip60 does not affect the regulation of DDR genes by PRMT5. Given the role of Tip60 in DRR, PRMT5-associated splicing of Tip60 likely regulates DSB repair choice but not DSB repair efficiency or at least does not affect PRMT5-associated transcriptional regulation of genes involved in DDR.

PRMT5 Regulates the Expression of DDR Genes in Multiple Cancer Cell Lines, and PRMT5 Expression Positively Correlates with DDR Genes in Human Cancer Tissues

To extend our findings and determine if the role of PRMT5 in DSB repair is conserved across multiple cell types, we performed similar experiments in AR-negative prostate cancer cells (DU145), luminal breast cancer cells (MCF7), glioblastoma cells (U87MG), and non-cancerous HEK293T cells. Inhibition of PRMT5 by BLL3.3 hindered repair of IR-induced DSBs as the cells retained significantly more γH2AX foci 6 h following IR treatment (Figures 7A and S7A–S7E). Although DDR genes were generally upregulated upon IR, targeting PRMT5 also caused a decrease in the expression of IR-induced DSBs in LNCaP cells (Figures S6C and S6D). This is consistent with another study reporting that knockdown of RuvBL1 had no effect on IR-induced 53BP1 foci in hematopoietic cells (Hamard et al., 2018). Therefore, methylation of RuvBL1 by PRMT5 likely affects DSB repair choice (favoring HR over NHEJ) but not the overall efficiency of repair, whereas the transcriptional activation of DDR genes by PRMT5 is likely required for repair of DSBs.

To assess potential clinical significance of our findings, we analyzed mRNA expression in 32 clinical cancer datasets achieved from The Cancer Genome Atlas (TCGA) Pan-Cancer analysis (The Cancer Genome Atlas Research Network et al., 2013). We focused on PRMT5, pICln, MEP50, AR, and DDR genes, which were identified as primary target genes of both PRMT5 and AR. The expression of PRMT5 correlated positively with DDR genes in almost all cancers (Figures 7C and S8A). As a control, we assessed if PRMT5 generally correlated with the expression of all genes in the transcriptome. As expected, there was no correlation across the cancer datasets (Figure 7C). PRMT5 expression generally did not correlate with AR and varied significantly for individual cancer types (Figures 7C and S8A). However, the strength of correlations between PRMT5 and several AR target genes involved in DDR seemed independent of the correlation between PRMT5 and AR (Figure S8A). To assess this further, we sorted the cancer types into three groups based on the correlation...
coefficient between PRMT5 and AR: positively correlated, negatively correlated, and not correlated. We observed no difference in the correlation between PRMT5 and DDR genes when the cancer types were stratified (Figure 7D), indicating that PRMT5 correlates positively with DDR genes independently of any correlation with AR. This leaves the possibility that AR target genes involved in DDR may also be primary target genes of PRMT5. However, similar RT-qPCR and ChIP-qPCR experiments revealed that only DNAPKcs is likely a target gene of PRMT5 (Figures S4A–S4F). DNAPKcs also had the highest correlation with PRMT5 across the 32 clinical cancer datasets (Figure S8A), further implicating DNAPKcs as a PRMT5 target gene.

As our data suggested that pICln, but not MEP50, cooperates with PRMT5 to regulate DDR genes, we also analyzed the correlations between MEP50 or pICln and the same DDR genes. Although MEP50 expression positively correlated with some DDR genes in some cancers (Figures 7E and S8A), pICln exhibited significantly stronger correlations with these DDR genes than MEP50 in almost all cancers (Figures 7E and S8A). Furthermore, PRMT5 correlated more significantly with pICln than MEP50 (Figure S8B). Collectively, our results suggest that PRMT5 and pICln play a conserved role in activating expression of genes required for the repair of IR-induced DSBs.

**DISCUSSION**

**PRMT5 Functions as an Epigenetic Activator to Regulate the Repair of DSBs**

Upon recognition of DNA DSBs, repair proteins (such as RAD51, BRCA1, and BRCA2) are transiently upregulated to facilitate repair through HR or NHEJ (Khalil et al., 2012; Rieger, 2004; Russell et al., 2003). Although this transient upregulation is required for cell survival following genotoxic stresses, there is a long-standing question of how proteins are quickly upregulated to promote repair of DNA damage. Here, we present evidence that PRMT5 functions as a master epigenetic activator of DDR genes to facilitate the repair of DSBs.

In this study, we determined that PRMT5 activated transcription of multiple genes that encode well-characterized repair proteins involved in HR (RAD51, RAD51AP1, RAD51D, BRCA1, and BRCA2) and NHEJ (NHEJ1 and DNAPKcs). DSB repair occurs in three phases: (1) recognition of DSBs via sensor proteins, (2) initiation of repair by repair proteins, and (3) resolution of repair (Thompson, 2012). Our studies suggest that PRMT5 primarily regulates the expression of repair proteins as opposed to DNA damage sensors or proteins involved in the resolution of repair. Since we also confirmed that PRMT5 regulated the expression of several other genes involved in various phases of DDR by RT-qPCR (Figure S3G), it remains to be determined whether these genes are also target genes of PRMT5.

The epigenetic regulation of genes is cell type, temporal, and context dependent. Our data suggest that PRMT5 likely activates transcription of DDR genes in a variety of cell types. However, we cannot rule out the possibility that PRMT5 regulates different DDR genes in different cells. For example, although we determined that PRMT5 activated transcription of RAD51, Clarke et al. demonstrated that depletion of PRMT5 impaired HR (reduced IR-induced RAD51 and BRCA1 foci) without affecting the expression of RAD51 or changes in cell cycle (Clarke et al., 2017). There are a few possible explanations: (1) their experiment was performed in HeLa-shPRMT5 stable cell lines and were not performed in inducible knockdown lines. It is possible that these cells compensated for depleted PRMT5 although all experiments were conducted on low passage cells to minimize effects of chronic PRMT5 depletion. (2) PRMT5 may not regulate RAD51 expression in HeLa cells. (3) HeLa cells may respond differently to depleted PRMT5 as evidenced by a lack of cell-cycle changes in HeLa cells that we and others have observed in other cell lines (Lim et al., 2014; Scoumanne et al., 2009; Wei et al., 2012; Yang et al., 2016). As an epigenetic regulator, it is possible that PRMT5 may not regulate the same cohort of DDR genes in every tissue but rather regulates the same pathways such as HR, NHEJ, and G2 arrest.

During preparation of this manuscript, Braun et al reported that PRMT5 post-transcriptionally regulates the splicing out of detained introns (DIs) of genes to modulate gene expression (Braun et al., 2017). However, our analysis of their data showed that the majority of DEGs we identified either do not contain DIs or DI splicing of our DEGs was not affected by PRMT5 targeting. Additionally, Tan et al. reported that PRMT5 is required for appropriate splicing in hematopoietic stem cells and that targeting PRMT5 causes increased intron retention and exon skipping events (Tan et al., 2019). In their study, they performed functional enrichment analysis on alternative splicing events upon PRMT5 knockdown and they identified that genes associated with “DNA repair” were enriched. However, there was little overlap between the genes we validated.
as PRMT5 target genes (RAD51, RAD51AP1, RAD51D, BRCA1, BRCA2, NHEJ1, DNAPKcs, and WEE1) and genes they identified as splicing targets. Interestingly, they functionally validated five splicing targets (FANCA, FANCG, MUTYH, RET1, and RAD52), and identified both FANCA and FANCG as “IR+ only” downregulated DEGs in their RNA-seq analysis. However, we did not pursue further validation of these genes. Overall, our findings are likely independent of potential splicing changes upon PRMT5 knockdown, and the role of PRMT5 in transcriptional regulation of DDR genes likely mediates the transient upregulation of repair proteins upon DNA damage.

**PRMT5 Is Required for Efficient Repair of DSBs**

We demonstrate that PRMT5 is required for efficient repair of DSBs. Interestingly, knockdown of PRMT5 alone caused an increase in spontaneous DSBs independent of external DNA damage inducers (Figures S2A and S2B), indicating that PRMT5 is required to repair endogenous DSBs. Two recent studies have also demonstrated that PRMT5 is required for efficient repair of DSBs in additional cell lines (Clarke et al., 2017; Hamard et al., 2018). We provide evidence that the activation of gene expression by PRMT5 is essential to DSB repair efficiency, whereas the regulation of RuvBL1 and Tip60 by PRMT5 likely only affects DSB repair choice. Specifically, PRMT5-catalyzed methylation of RuvBL1 and PRMT5-associated splicing of Tip60 may promote HR over NHEJ, yet the DSB can be repaired regardless of pathway choice. Therefore, observation that PRMT5 is required for efficient repair of IR-induced DSBs is most likely explained by our finding that PRMT5 activates transcription of DDR genes. Because Tip60 is required for ATM activation (Bhoumik et al., 2008; Sun et al., 2005) and ATM phosphorylates H2AX to form γH2AX foci and signals the initiation of DSB repair (Burma et al., 2001), we did not perform γH2AX foci analysis to assess repair of IR-induced DSBs. Because Tip60 has been shown to be essential for γH2AX foci formation (Ikura et al., 2000; Murr et al., 2006), we would have observed a decrease in γH2AX regardless if knockdown of Tip60 would affect repair of IR-induced DSBs.

**PRMT5 Regulates DSB Repair Independently of AR**

We recently reported that PRMT5 is an epigenetic activator of AR (Deng et al., 2017). In prostate cancer cells, AR has been reported to regulate DSB repair via HR and NHEJ (Asim et al., 2017; Goodwin et al., 2013; Li et al., 2017; Polkinghorn et al., 2013; Spratt et al., 2015; Tarish et al., 2015). Upon IR, AR is recruited to the promoter of DDR genes to activate their expression (Goodwin et al., 2013) (~8–24 h post IR), albeit at a much later time point than the recruitment of PRMT5 to the promoter of DDR genes (~1 h post IR). Knockdown or inhibition of AR signaling has also been shown to directly impair HR (Asim et al., 2017; Polkinghorn et al., 2013), and recent studies suggest that AR may be essential for HR particularly in castration-resistant prostate cancer (CRPC) (Asim et al., 2017; Goodwin et al., 2013; Li et al., 2017). However, AR’s role in regulating NHEJ is more established in that AR transcriptionally activates genes involved in NHEJ (Goodwin et al., 2013; Polkinghorn et al., 2013; Spratt et al., 2015; Tarish et al., 2015).

As we reported that targeting PRMT5 decreases AR expression (Deng et al., 2017), the requirement of PRMT5 for efficient repair of DSBs could be mediated through the regulation of AR. Indeed, we demonstrated that targeting PRMT5 caused a decrease in AR expression and concomitant decrease in the expression of AR target genes involved in NHEJ (Ku80, XRCC4, and DNAPKcs). However, several pieces of evidence in our study suggest that PRMT5 also regulates repair of DSBs independently of AR: (1) PRMT5 targeting sensitized both AR-positive and AR-negative prostate cancer cells to IR; (2) exogenous expression of AR only partially rescued the impairment of IR-induced DSB repair by PRMT5 knockdown; (3) targeting PRMT5 hindered the repair of IR-induced DSBs in AR-negative DU145 cells and several other cancer cell lines with varying AR expression level; and (4) in clinical cancer datasets, PRMT5 expression was positively correlated with the expression of DDR target genes regardless of its correlation with AR. Collectively, these data strongly suggest that although targeting PRMT5 may mimic targeting AR to sensitize prostate cancer cells to IR, PRMT5 can regulate DSB repair independently of AR expression.

**PRMT5 Likely Regulates the Repair of IR-Induced DSBs via Multiple Mechanisms**

In this study, we determined that PRMT5 is required for efficient repair of DSBs via activation of DDR genes. Additionally, there are several reports suggesting that PRMT5 may regulate the repair of DNA damage via multiple mechanisms. As detailed above, recent reports show that PRMT5 regulates the DSB repair choice process and promotes HR through methylation of RuvBL1 (Clarke et al., 2017) and altered splicing of Tip60 (Hamard et al., 2018). Indeed, RuvBL1 was identified in our mass-spec analysis (peptide fragment TISHVIIGLK) as a potential interacting protein of PRMT5 in LNCaP cells. Therefore, our observation that
PRMT5 knockdown decreased HR-associated RAD51 foci may be partially explained by these previous results.

PRMT5 can also regulate protein expression via splicing (Braun et al., 2017; Tan et al., 2019). These two studies identified some PRMT5 splicing targets involved in DDR. For example, PRMT5 is required to maintain appropriate expression of functional RAD52 (Tan et al., 2019), and recent reports demonstrate the importance of RAD52 to HR (Hanamshet et al., 2016; Mahajan et al., 2019; Manthey et al., 2017). Future studies may determine if PRMT5-associated splicing directly affects the repair of IR-induced DSBs.

PRMT5 has also been shown to methylate and regulate several proteins associated with DDR: p53 (Du et al., 2016; Durant et al., 2009; Jansson et al., 2008; Scoumanne et al., 2009), E2F1 (Cho et al., 2012; Wu et al., 2015; Zheng et al., 2013), FEN1 (Guo et al., 2010, 2012), RAD9 (He et al., 2011), KLF4 (Hu et al., 2015), and TDP1 (Rehman et al., 2018). As detailed in these studies, DNA damage via etoposide, hydroxyurea, doxorubicin, and UV can induce PRMT5-catalyzed methylation of these non-histone substrates, which alters the cellular response to DNA damage. For example, PRMT5-catalyzed methylation of p53 altered binding to p53 target genes, which promoted cell-cycle arrest and inhibited apoptosis (Jansson et al., 2008). However, these studies did not identify a direct role for PRMT5 in the repair of DSBs or in the response to IR. For example, PRMT5-catalyzed methylation of RAD9 was essential to the cellular response to hydroxyurea but did not play a significant role in the cellular response to IR. It is likely that there are unknown PRMT5 substrates involved in DDR, and future studies may determine if PRMT5-catalyzed methylation of these proteins directly affects DSB repair efficiency.

In various yeast species, the PRMT5 homologue Hsl7 was shown to interact with and promote degradation of WEEl homologues to promote G2 progression independently of its methyltransferase activity (Cid et al., 2001; Theesfeld et al., 2003; Yamada et al., 2004). Although it is unknown if PRMT5 interacts with WEEl protein in human tissues, the studies in yeast contrast with our study in which PRMT5 activated transcription of WEEl and promoted DNA damage-induced G2 arrest. The opposing post-translational and transcriptional regulation of WEEl by PRMT5 may be modulated by PRMT5 methyltransferase activity and/or the absence or presence of DNA damage. In fact, the PRMT5-mediated changes in cell cycle in the Xenopus egg are independent of transcription because Xenopus egg extracts can cycle without de novo mRNA transcription (Yamada et al., 2004). Therefore, PRMT5 likely modulates WEEl-mediated cell-cycle changes in multiple ways.

plCln May Function as a Cofactor of PRMT5 to Epigenetically Regulate Gene Expression Independently of MEP50

There is a long-standing view in the field that the cofactor MEP50 is required for PRMT5 methyltransferase activity and epigenetic function (Burgos et al., 2015; Chen et al., 2017; Karkhanis et al., 2011; Stopa et al., 2015). In solution, PRMT5 can exist as a homodimer or homotetramer. With MEP50, PRMT5 forms a heterooctomeric complex (PRMT5\(4\):MEP50\(4\)) (Antonyssamy et al., 2012). Consistent with these structural studies, biochemical studies have provided evidence that purified PRMT5:MEP50 complex can catalyze dimethylation of various histone substrates including H4R3 (Burgos et al., 2015; Wang et al., 2014). However, our data suggest that PRMT5 works with plCln for the transcriptional activation of DDR genes via H4R3me2s. This is inconsistent with a previous report where Pesiridis et al showed that titration of plCln decreased H3 and H4 methylation by PRMT5 in an in vitro methylation assay (Pesiridis et al., 2009). However, as PRMT5 functions in a larger complex, the in vitro assay using proteins from a bacterial expression system might not recapitulate the biochemical and cellular conditions required for H4R3me2s in vivo. In our study, knockdown of MEP50 did not affect the expression of PRMT5 target genes involved in DDR, and MEP50 was not present at any of the target gene promoters characterized. Instead, plCln was present at the promoter regions of PRMT5 target genes along with H4R3me2s, and knockdown of plCln caused a decrease in PRMT5 target gene expression and impaired IR-induced DSB repair. Thus, it is likely that plCln may function as a cofactor of PRMT5 to activate transcription of DDR genes. As the epigenetic regulation of gene expression likely involves formation of a larger protein complex in a gene-specific manner, future characterization of PRMT5 and its cofactors or interacting proteins in vivo will provide mechanistic insight into the regulation of expression of PRMT5 target genes.

Although PRMT5-catalyzed histone methylation is predominantly repressive (Stopa et al., 2015), recent studies show PRMT5 can function as an activator of gene expression (Deng et al., 2017; Chen et al., 2017; Scoumanne et al., 2009).
Activation or repression is not likely dependent solely on PRMT5-catalyzed histone methylation, as H4R3me2s has been shown to be both a repressive (Chen et al., 2017) and active chromatin mark (Deng et al., 2017). Therefore, additional factors are required to mediate the positive or negative epigenetic regulation by PRMT5. Because PRMT5 does not contain a DNA binding domain, additional proteins that recruit PRMT5 to sites on the genome may play a role in mediating the epigenetic function of PRMT5. Future studies will elucidate the full structure and interactome of PRMT5 on DNA and will determine differences between its active and repressive complexes. This will also provide an answer for how the same PRMT5-catalyzed histone modifications can mediate gene repression and activation. As we reported that PRMT5 functions as an epigenetic activator of AR expression (Deng et al., 2017), future work will determine if this is dependent on pICln. It is possible that pICln promotes activation by PRMT5, whereas other cofactors, such as MEP50, may promote repression by PRMT5.

**PRMT5 Targeting May Be Explored for Cancer Treatment**

According to the American Cancer Society, over half of all cancer patients receive RT. RT induces DSBs in DNA, which are lethal to cells if not repaired. Although potentially curative, tumors can still regrow following RT. For example, 10% of prostate cancer patients with low-risk disease and 30-50% of patients with high-risk disease treated with RT still experience tumor recurrence (Boorjian et al., 2011; D’Amico et al., 2008). Thus, identification of novel therapeutic targets to enhance RT will likely reduce cancer mortality.

PRMT5 is overexpressed in many cancers, and its overexpression correlates with poor prognosis (Karkhanis et al., 2011; Stopa et al., 2015; Yang and Bedford, 2013). Our findings suggest that PRMT5 overexpression may increase the efficiency of DSB repair and confer survival advantages particularly following DNA-damaging treatments. For example, upregulation of RAD51, a putative PRMT5 target gene, has been shown to promote resistance to DNA damaging agents (Petermann et al., 2010; Schild and Wiese, 2010) and decreasing RAD51 expression sensitizes cancer cells to IR (Hayman et al., 2012). Because targeting DSB repair is a validated therapeutic approach for cancer treatment (Gavande et al., 2016), our findings that PRMT5 expression positively correlates with multiple DDR genes across clinical cancer datasets strongly suggests that PRMT5 targeting may be explored as a monotherapy or in combination with RT or chemotherapy for cancer treatment. PRMT5 may also be a particularly attractive therapeutic target for prostate cancer patients because targeting PRMT5 decreases AR expression (Deng et al., 2017) and targeting AR signaling via ADT enhances RT for prostate cancer patients (Golabek et al., 2016).

One criticism of PRMT5 targeting is potential systemic side effects as epigenetic regulators typically have essential roles in various tissues. Although targeting PRMT5 does not affect the growth of AR-negative DU145 and PC3 cells as well as normal prostate RWPE-1 cells (Deng et al., 2017), we do find that targeting PRMT5 inhibits repair of IR-induced DSBs in non-cancerous HEK293T cells. It is reasonable to suspect that targeting PRMT5 may also sensitize adjacent normal tissue to RT. Given advances in RT, the amount of adjacent normal tissue that is irradiated is minimized. Thus, it is likely that the combination of PRMT5 targeting and RT will allow for either a lower dose of drug or IR to limit side effects. Alternatively, targeted delivery of PRMT5 inhibitors as radiosensitizers will circumvent systemic toxicity. This can be effectively achieved through prostate specific membrane antigen-based delivery (Rowe et al., 2016). Nevertheless, our findings here provide convincing evidence that PRMT5 functions as a master epigenetic regulator to activate transcription of DNA damage repair genes and is a potential therapeutic target to enhance RT or chemotherapy for cancer treatment.

**Limitations of the Study**

We present evidence that PRMT5 cooperates with pICln to function as a master epigenetic activator of DDR genes in various cell types. Although this potentially explains the long-standing question of how repair proteins are quickly upregulated to promote the repair of DNA damage, the precise molecular mechanisms on how PRMT5 and pICln function together to activate gene expression remain to be determined. Our findings also suggest that the regulatory role of PRMT5 in the activation of DDR genes is independent of its canonical cofactor MEP50: MEP50 was not present at the promoter of DDR genes, and knockdown of MEP50 did not affect expression of DDR genes nor did it affect repair of IR-induced DSBs. Although we provide several lines of evidence suggesting that pICln, but not MEP50, may participate in transcriptional regulation of DDR genes by PRMT5, it is possible that our knockdown of MEP50 was not sufficient to prevent the regulation of DDR gene expression. Thus, future studies with CRISPR-based knockout or PRMT5:MEP50 protein-protein interaction inhibitors may be needed to further evaluate a potential role...
for MEP50 in the regulation of PRMT5 target genes involved in DDR. Given that previous biochemical assays demonstrate that PRMT5 requires MEP50 for methyltransferase activity, further biochemical assays of PRMT5 with its cofactors in the presence of nucleosomes may provide mechanistic insight into the modulation of PRMT5 catalytic activity by its cofactors in the context of transcriptional regulation. These studies combined with both structural analysis of the PRMT5 complex at the promoter of target genes involved in DDR and genome-wide analyses such as ChIP-seq and ATAC-seq will likely provide mechanistic evidence for how PRMT5 functions with pICln and/or other cofactors to regulate transcription of DDR target genes.

METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.

DATA AND CODE AVAILABILITY
RNA-seq datasets generated in this study are available at the Gene Expression Omnibus (GEO) under accession number GSE111620.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.100750.

ACKNOWLEDGMENTS
This study was partially supported by grants from U.S. Army Medical Research Acquisition Activity, Prostate Cancer Research Program (PC11190, PC120512, PC150697) and NCI RO1CA212403, and Purdue University Center for Cancer Research Small Grants. Primary RNA-seq analysis and TCGA data analysis were performed by the Collaborative Core for Cancer Bioinformatics (C3B) shared by Indiana University Simon Cancer Center (P30CA082709) and Purdue University Center for Cancer Research (P30CA023168) with support from the Walther Cancer Foundation. DNA sequencing was conducted by the Genomic Core Facility supported by NCI CCSG CA23168 to Purdue University Center for Cancer Research. We would like to thank Indiana University Precision Health Initiative. J.L.O. is a recipient of the Indiana Clinical and Translational Sciences Institute (CTSI) Pre-Doctoral Fellowship, which was made possible with partial support from Grant Numbers TL1 TR001107, TL1 TR002531, UL1 TR001108, and UL1 TR002529 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. We would also like to thank Dr. Liang Cheng and Dr. Jeannie Poulson Plantenga for providing their mentoring to J.L.O. and insightful comments on the study.

AUTHOR CONTRIBUTIONS
Conceptualization: J.L.O., J.H. (consultations for clinical aspects), and C.D.H.; Methodology: J.L.O., X.D., and E.B.; Validation: J.L.O., E.B., S.L.T., A.M.A., and X.D.; Formal Analysis: J.L.O., S.L., and J.W.; Investigation: J.L.O., E.B., S.L.T., A.M.A., S.L., and X.D.; Resources: X.D.; Data Curation: J.L.O.; Writing—Original Draft: J.L.O.; Writing—Review & Editing: J.L.O., E.B., S.L.T., A.M.A., J.W., and C.D.H.; Visualization: J.L.O., S.L., and J.W.; Supervision: J.W. and C.D.H.; Project Administration: J.L.O. and C.D.H.; Funding Acquisition: J.H., C.L., J.W., and C.D.H.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
Alinari, L., Mahasenan, K.V., Yan, F., Karkhanis, V., Chung, J.-H., Smith, E.M., Quinion, C., Smith, P.L., Kim, L., Patton, J.T., et al. (2015). Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood 125, 2530–2543.

Antonyatty, S., Bondy, Z., Campbell, R.M., Doyle, B., Druzinia, Z., Gheyi, T., Han, B., Junghein, L.N., Qian, Y., Rauch, C., et al. (2012). Crystal structure of the human PRMT5-MEP50 complex. Proc. Natl. Acad. Sci. USA 109, 17960–17965.

Asim, M., Tarish, F., Zecchini, H.I., Sanjiv, K., Gelali, E., Massie, C.E., Baridi, A., Warren, A.Y., Zhao, W., Ogris, C., et al. (2017). Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat. Commun. 8, 374.
Bhoumik, A., Singha, N., O’Connell, M.J., and Ronai, Z.A. (2008). Regulation of TIP60 by ATF2 modulates ATM activation. J. Biol. Chem. 283, 17605–17614.

Boorjian, S.A., Karnes, R.J., Viterbo, R., Rangel, L.J., Bergstralh, E.J., Horwitz, E.M., Blute, M.L., and Buyyounouski, M.K. (2011). Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117, 2883–2891.

Braun, C.J., Stanciu, M., Bouts, P.L., Patterson, J.C., Calligaris, D., Higuchi, F., Neupane, R., Fenoglio, S., Cahill, D.P., Wakiimoto, H., et al. (2017). Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma. Cancer Cell 32, 411–426.e11.

Burgos, E.S., Wilczek, C., Onikubo, T., Bonanno, J.B., Jansong, J., Reimer, U., and Shechter, D. (2015). Histone H2A and H4 N-terminal tails are positioned by the MEPSO WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase. J. Biol. Chem. 290, 9674–9689.

Burma, S., Chen, B.P., Murphy, M., Kurimasa, A., and Chen, D.J. (2001). ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276, 42462–42467.

Chari, A., Golas, M.M., Klingenheber, M., Neuenkirchen, N., Sander, B., Engbrecht, C., Sickmann, A., Stark, H., and Fischer, U. (2008). An assembly chromatinosome with the SMN complex to generate splicingosomal SmRNPs. Cell 135, 497–509.

Chen, H., Lorton, B., Gupta, V., and Shechter, D. (2017). A TGFβ-PRMT5-MEPSO axis regulates cancer cell invasion through histone H4 and arginine methylated coupling transcriptional activation and repression. Oncogene 36, 373–386.

Cho, E.-C., Zheng, S., Munro, S., Liu, G., Carr, S.M., Moetlenbrink, J., Lu, Y.-C., Simson, L., Klf14, O., Kowalcyzy, R., et al. (2012). Arginine methylation controls growth regulation by EZF1-EMBO J. 31, 1785–1797.

Cid, V.J., Shulewitz, M.J., McDonald, K.L., and Thorner, J. (2001). Dynamic localization of the S6e1 regulator Has7 during the Saccharomyces cerevisiae cell cycle. Mol. Biol. Cell 12, 1645–1669.

Clarke, T.L., Sanchez-Bailon, M.P., Chiang, K., Reynolds, J.J., Herrera-Ruiz, J., Banderias, T.M., Matias, P.M., Maslen, S.L., Skehel, J.M., Stewart, G.S., et al. (2011). PRMT5-Dependent methylation of the Tip60 coactivator RUVBL1 is a key regulator of homologous recombination. Mol. Cell 65, 900–916.e7.

Deng, X., Shao, G., Zhang, H.T., Li, C., Zhang, D., Cheng, L., Eliezer, B.D., Pili, R., Ratliff, T.L., Huang, J., et al. (2017). Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene 36, 1223–1231.

Du, W., Amaramchitha, S., Erden, O., Wilson, A., and Pang, Q. (2016). The Fanconi anemia pathway controls oncogenic response in hematopoietic stem and progenitor cells by regulating PRMT5-mediated p53 arginine methylation. Oncotarget 7, 60005–60020.

Durant, S.T., Cho, E.C., and La Thangue, N.B. (2009). p53 methylation—the argument is clear. Cell Cycle 8, 801–802.

D’Amico, A.V., Chen, M.-H., Renshaw, A.A., Loffredo, B., and Kantoff, P.W. (2008). Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J. Clin. Oncol. 26, 2979–2983.

Friesen, W.J., Paushkin, S., Wyse, A., Massenet, S., Peuridis, G.S., Van Duyn, G., Rappsilber, J., Mann, M., and Dreyfuss, G. (2002). A novel WD repeat protein component of the methylosome binds Sm proteins. J. Biol. Chem. 277, 8243–8247.

Furuta, T., Takemura, H., Lii, Y.-Z., Aune, G.J., Redon, C., Seldenikova, A.O., Pilch, D.R., Rogakou, E.P., Celeste, A., Chen, H.T., et al. (2003). Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J. Biol. Chem. 278, 20303–20312.

Gavande, N.S., VanderVere-Carozza, P.S., Hinshew, H.D., Jalal, S.I., Sears, C.R., Pawelczak, K.S., and Turchi, J.J. (2016). DNA repair targeted suppression therapy: the past or future of cancer treatment? Pharmacol. Ther. 160, 65–83.

Golabek, T., Belaya, J., Druwa, T., Kołodziej, A., Skoneczna, I., Milecki, P., Dobruch, J., Wu, Z., Wang, Y., Loh, T., Kowolik, C., Jamsen, J., et al. (2012). Sequential posttranslational modifications program FEN1 degradation during cell-cycle progression. Mol. Cell 47, 444–456.

Hamard, P.-J., Santiago, G.E., Liu, F., Karl, D.L., Martinez, C., Man, N., Mookhtiar, A.K., Duffort, S., Greenblatt, S., Verdun, R.E., et al. (2018). PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes. Cell Rep. 24, 2643–2657.

Hanamshet, K., Mazina, O., and Mazin, A. (2016). Reappearance from obscurity: mammalian Rad52 in homologous recombination. Genes 7, 63.

Hayman, T.J., Williams, E.S., Jamal, M., Shankavaram, U.T., Camphausen, K., and Tofilon, P.J. (2012). Translation initiation factor eIF4E is a target for tumor cell radiosensitization. Cancer Res. 72, 2362–2372.

He, W., Ma, X., Yang, X., Zhao, Y., Qiu, J., and Hang, H. (2011). A role for the arginine methylation of Rad9 by checkpoint control and cellular sensitivity to DNA damage. Nucleic Acids Res. 39, 4719–4727.

Heidenreich, A., Bastian, P.J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Weiigel, T., Zattoni, F., et al. (2014). EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 65, 467–479.

Hu, C.-D., Chinenov, Y., and Kerpola, T.K. (2002). Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol. Cell 9, 789–798.

Hu, D., Gur, M., Zhou, Z., Gamper, H., Hung, M.-C., Fujita, N., Lan, L., Bahar, I., and Wan, Y. (2015). Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis. Nat. Commun. 6, 8419.

Ikura, T., Ogryzko, V.V., Grigoriev, M., Groisman, R., Wang, J., Horkosh, M., Scully, R., Qin, J., and Nakatani, Y. (2000). Involvement of the Tip60 histone acetyltransferase complex in DNA repair and apoptosis. Cell 102, 463–473.

Janssen, M., Durant, S.T., Cho, E.-C., Sheahan, S., Edelmann, M., Kessler, B., and La Thangue, N.B. (2008). Arginine methylation regulates the p53 response. Nat. Cell Biol. 10, 1431–1439.

Karkhanis, V., Hu, Y.-J., Biaocchi, R.A., Imbalzano, A.N., and Sif, S. (2011). Versatility of PRMT5-induced methylation in growth control and development. Trends Biochem. Sci. 36, 633–641.

Khalil, H., Tummala, H., and Zhelev, N. (2012). DNA methylation and ubiquitination regulates KLF4-mediated genome stability and carcinogenesis. Nat. Commun. 3, 793–805.
possibly through PRMT5-E2F-1 pathway. Sci. Rep. 4, 4505.

Yamada, A., Duffy, B., Perry, J.A., and Kornbluth, S. (2004). DNA replication checkpoint control of Wee1 stability by vertebrate Hsl7. J. Cell Biol. 167, 841–849.

Yang, Y., and Bedford, M.T. (2013). Protein arginine methyltransferases and cancer. Nat. Rev. Cancer 13, 37–50.

Yang, H., Zhao, X., Zhao, L., Liu, L., Li, J., Jia, W., Liu, J., and Huang, G. (2016). PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma. Oncotarget 7, 72131–72147.

Zhang, H.-T., Zeng, L.-F., He, Q.-Y., Tao, W.A., Zha, Z.-G., and Hu, C.-D. (2016). The E3 ubiquitin ligase CHIP mediates ubiquitination and proteasomal degradation of PRMT5.

Zheng, S., Moehlenbrink, J., Lu, Y.-C., Zalmas, L.-P., Sagum, C.A., Carr, S., McGouran, J.F., Alexander, L., Fedorov, O., Munro, S., et al. (2013). Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1. Mol. Cell 52, 37–51.
Supplemental Information

PRMT5 Cooperates with pICln to Function as a Master Epigenetic Activator of DNA Double-Strand Break Repair Genes

Jake L. Owens, Elena Beketova, Sheng Liu, Samantha L. Tinsley, Andrew M. Asberry, Xuehong Deng, Jiaoti Huang, Chenglong Li, Jun Wan, and Chang-Deng Hu
Figure S1. PRMT5 regulates the repair of IR-induced DSBs in prostate cancer cells. Related to Figure 2.

(A) Migration of DNA via neutral comet assay at the indicated time points post the indicated dose of IR in LNCaP-shPRMT5 cells without (Dox-) PRMT5 knockdown. The 5 m time point indicates how much DNA damage is induced by the indicated dose of IR. The 2 h time point indicates how much DNA damage is repaired within 2 h post the indicated dose of IR.

(B) Quantification of DNA damage in each individual cell via calculating the relative amount of DNA in the tail vs. head of the comet (’% tail DNA’) from A.

(C) Migration of DNA via neutral comet assay 2 h post indicated dose of IR in LNCaP-shPRMT5 cells with (Dox+) and without (Dox-) PRMT5 knockdown.

(D) Quantification of DNA damage in each individual cell via calculating the relative amount of DNA in the tail vs. head of the comet (’% tail DNA’) from C.

Box and whiskers plot in B and D show the median value (line), interquartile range (box), and 10-90 percentile (whiskers) of pooled ’% tail DNA’ values from 3 independent experiments. Statistical analysis comparing experimental to the control (’Dox’) was performed using Mann-Whitney U-test (**** P ≤ 0.0001 and NS P > 0.05).
Figure S2. PRMT5 regulates the repair of etoposide-induced DSBs in prostate cancer cells. Related to Figure 2.

(A) DSBs after 48 h of etoposide (E) or DMSO (D) treatment in LNCaP-shPRMT5 cells with (Dox+) and without (Dox-) PRMT5 knockdown.

(B) Quantification of DSBs in each individual cell from A as described in Figure 2B.

(C) PRMT5 expression in cells from A.

(D) Quantification of PRMT5 expression in images from C. For each biological replicate, values were normalized to the value for ‘Dox-,DMSO’ to calculate the fold change in protein expression upon treatment.

(E) Representative western blot showing changes in protein expression in cells from A. Values shown indicate the intensity relative to ‘Dox-,DMSO’ for the biological replicate used as the representative western blot.

(F) Quantification of protein expression via western blotting from E. For each biological replicate, values were normalized to the value for ‘Dox-,DMSO’ to calculate the fold change in protein expression upon treatment.

Fluorescence images in A and C are representative immunocytochemistry images (blue = DAPI, green = γH2AX, and red = PRMT5). Bars in B are the mean ± s.d. of 4 independent experiments and bars in D and F are the mean ± s.d. of 3 independent experiments. Statistical analysis was performed using Brown-Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test (* P ≤ 0.05; ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001, NS P > 0.05).
Figure S3. PRMT5 activates transcription of genes that encode proteins involved in the repair of DSBs. Related to Figure 4.

(A) Quantification of mRNA via RT-qPCR at the indicated time point post 2 Gy IR in irradiated (IR+) and non-irradiated (IR-) LNCaP-shPRMT5 cells with (Dox+) and without (Dox-) PRMT5 knockdown. For each biological replicate, the value for Dox+ was normalized to the value for Dox- to calculate the fold change in mRNA expression upon PRMT5 knockdown (See also Figure 4B).

(B)-(E) Representative western blots showing protein expression at 6 h post 2 Gy IR in irradiated (IR+) and non-irradiated (IR-) LNCaP-shPRMT5 cells with (Dox+) and without (Dox-) PRMT5 knockdown. Values shown indicate the intensity relative to IR- for the biological replicate used as the representative western blot.

(F) Quantification of protein expression via western blotting from B-E. For each biological replicate, values were normalized to the value for 'Dox-/IR-' to calculate the fold change in protein expression upon treatment.

(G) Quantification of mRNA via RT-qPCR 24 h post 2 Gy IR in irradiated (IR+) and non-irradiated (IR-) LNCaP- shPRMT5 cells with (Dox+) and without (Dox-) PRMT5 knockdown. For each biological replicate, the value for Dox+ was normalized to the value for Dox- to calculate the fold change in gene expression upon PRMT5 knockdown (See also Figure 4A and 4F).

Bars in A, F, and G are the mean ± s.d. of 3 independent experiments. Statistical analysis comparing experimental to the control ('Dox-' or 'Dox- / IR-') was performed using Brown-Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test (* P ≤ 0.05; ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001, NS P > 0.05).
Figure S4. PRMT5 likely functions as an epigenetic activator of DDR genes. Related to figure 4.

(A)-(F) Quantification of enrichment (A: PRMT5, B: H4R3me2s, C: H3R2me2s, D: H3R8me2s, E: H2AR3me2s and F: H3K9ac) at the promoter region of the indicated genes 1 h post 2 Gy IR in irradiated (IR+) and non-irradiated (IR-) LNCaP-shSC or shPRMT5 cells via ChIP-qPCR. For each biological replicate, the value for ChIP was normalized to the value for IgG to calculate the fold enrichment (See also Figures 4C-E and G-I).

All bars are the mean ± s.d. of 3 independent experiments. Statistical analysis was performed using Brown-Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test and the comparison to the control (‘shSC, IR-’) is shown (* P ≤ 0.05; ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001, NS P > 0.05).
Figure S5. pICln is also required for transcriptional activation of DDR genes and for efficient repair of DSBs. Related to Figure 5.

(A) Representative western blots showing protein expression at 2 h post 2 Gy IR in irradiated (IR+) and non-irradiated (IR-) LNCaP-shMEP50 cells with (Dox+) and without (Dox-) MEP50 knockdown. Values shown indicate the intensity relative to ‘Dox-,IR-’ for the biological replicate used as the representative western blot.

(B) Quantification of protein expression via western blotting from A. For each biological replicate, values were normalized to the value for ‘Dox-,IR-’ to calculate the fold change in protein expression upon treatment.

(C) Representative western blots showing protein expression at 2 h post 2 Gy IR in irradiated (IR+) and non-irradiated (IR-) LNCaP-shpICln cells with (Dox+) and without (Dox-) pICln knockdown. Values shown indicate the intensity relative to ‘Dox-,IR-’ for the biological replicate used as the representative western blot.

(D) Quantification of protein expression via western blotting from C. For each biological replicate, values were normalized to the value for ‘Dox-,IR-’ to calculate the fold change in protein expression upon treatment.

(E)-(F) Quantification of enrichment (E: MEP50 and F: pICln) at the promoter region of the indicated genes 1 h post 2 Gy IR in irradiated (IR+) and non-irradiated (IR-) LNCaP-shSC or shPRMT5 cells via ChIP-qPCR. Dox was applied to establish and maintain PRMT5 knockdown (shPRMT5) or express scramble control shRNA (shSC). For each biological replicate, the value for IP was normalized to the value for IgG to calculate the fold enrichment (See also Figure 5G and 5H).

(G)-(H) Quantification of enrichment (G: RioK1 and H: COPR5) at the promoter region of the indicated genes 1 h post 2 Gy IR via ChIP-qPCR in irradiated (IR+) and non-irradiated (IR-) LNCaP cells via ChIP-qPCR. For each biological replicate, the value for IP was normalized to the value for IgG to calculate the fold enrichment.

Bars in B and E-H are the mean ± s.d. of 3 independent experiments. Bars in D are the mean ± s.d. of 6 independent experiments. Statistical analysis for B, D, E, and F was performed using Brown-Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test and the comparison to the control (‘shSC, IR-’) is shown while for G and H, statistical analysis comparing experimental to the control (‘IR-’) was performed using Welch’s t-test (* P ≤ 0.05; ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001, NS P > 0.05).
Figure S6. The transcriptional regulation of DSB repair genes by PRMT5 is not dependent on RuvBL1 or Tip60. Related to Figure 4.

(A) Representative western blot showing the protein expression in LNCaP cells with (shRuvBL1) and without (control) RuvBL1 knockdown. Values shown indicate the intensity relative to control for the biological replicate used as the representative western blot.

(B) Quantification of protein expression via western blotting from A. For each biological replicate, values were normalized to the value for ‘control’ to calculate the fold change in protein expression upon RuvBL1 knockdown.

(C) DSBs 6 h post 2 Gy IR in LNCaP cells with (shRuvBL1) and without (control) RuvBL1 knockdown.

(D) Quantification of DSBs in each individual cell from C as described in Figure 2B. CFP was used as a transfection control such that RuvBL1 was knocked down solely in CFP+ cells.

(E) Representative western blot showing the protein expression in LNCaP cells with (shTip60) and without (control) Tip60 knockdown. Values shown indicate the intensity relative to control for the biological replicate used as the representative western blot.

(F) Quantification of protein expression via western blotting from E. For each biological replicate, values were normalized to the value for ‘control’ to calculate the fold change in protein expression upon Tip60 knockdown.

Fluorescence images in C are representative immunocytochemistry images (blue = DAPI, red = RuvBL1, and cerulean = CFP). Bars in B, D, and F are the mean ± s.d. of 3 independent experiments. Statistical analysis for B and F comparing experimental to the control (‘control’) was performed using Welch’s t-test while statistical analysis for D was performed using Brown-Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test (* P ≤ 0.05; ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001, NS P > 0.05).
Figure S7. The role of PRMT5 in the repair of DSBs is conserved in multiple cancer cell lines. Related to Figure 7.

(A)-(E) DSBs 6 h post 2 Gy IR in the indicated cell lines (A: LNCaP, B: DU145, C: MCF7, D: U87MG, E: HEK293T) with PRMT5 inhibition (BLL3.3) or without PRMT5 inhibition (DMSO) as described in Figure 2B. Fluorescence images in A–E are representative immunocytochemistry images (blue = DAPI, green = γH2AX, and red = PRMT5) (see also Figure 7A for statistical analysis).

(F)-(J) Quantification of mRNA via RT-qPCR 6 h post 2 Gy IR in the indicated irradiated (IR+) and non-irradiated (IR-) cell lines (F: LNCaP, G: DU145, H: MCF7, I: U87MG, J: HEK293T) with PRMT5 inhibition (BLL3.3) or without PRMT5 inhibition (DMSO). For each biological replicate, values were normalized to the value for ‘DMSO,IR-’ (untreated) to calculate the fold change in mRNA expression upon treatment. (See also Figure 7B).

Bars are the mean ± s.d. of 3 independent experiments. Statistical analysis comparing experimental to the control (‘DMSO,IR-’) was performed using Brown-Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test (* P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001, NS P > 0.05).
Figure S8. The expression of PRMT5 and pICln correlates with the expression of DDR genes in most human cancer tissues. Related to Figure 7.

(A) Heatmap of Spearman correlation values between the indicated DDR genes and either PRMT5, CLNS1A (pICln), or WDR77 (MEP50) at the mRNA level across 32 clinical cancer data sets. The right section shows the correlation values between AR and PRMT5, pICln, or MEP50, respectively. Red indicates a positive correlation while blue indicates a negative correlation. The cancer types (y-axis, not listed) were sorted by the mean value of correlations between PRMT5 and DDR genes. (See also Figures 7C-7E).

(B) Violin plot representation of Spearman correlation values between CLNS1A (pICln) or WDR77 (MEP50) and PRMT5. Box-and-whiskers plots in B show the median value (line) and interquartile range between the first and third quartiles (box). The upper whisker extended to the largest value no further than '1.5 x interquartile range' and the lower whisker extended to the smallest value at most '1.5 x interquartile range'. Statistical analysis was performed using Wilcoxon test and the p-values are displayed.
**LIST OF SUPPLEMENTAL FILES**

Table S1 - RNA-seq in IR- cells, Related to Figure 3G  
Table S2 - RNA-seq in IR+ cells, Related to Figure 3G  
Table S3 - DEGs in IR+ cells, Related to Figure 3H  
Table S4 - GO analysis, Related to Figure 3I  
Table S5 - IPA in IR+ cells, Related to Figure 3J  
Table S6 - Antibodies list, Related to Methods  
Table S7 - Primers list, Related to Methods  

**TRANSPARENT METHODS**

**Cell lines and cell culture.** LNCaP, DU145, PC3, and HEK293T were purchased from ATCC (Manassas, VA, USA) and cultured as described previously (Deng et al., 2017; Zhang et al., 2014). MCF7 cells were a gift from the Chun-Ju (Alice) Chang lab, and U87MG cells were a gift from the Emily Dykhuizen lab. Upon arrival, all cell lines were immediately expanded and aliquots were prepared and stored in liquid nitrogen. Cells were maintained for no longer than 30 passages or no longer than three months as described previously (Deng et al., 2011; Hsu and Hu, 2013). Cell line authentication for LNCaP cells was performed by IDEXX BioResearch (IMPACT I) and the absence of mycoplasma contamination for all cell lines was verified using LookOut® PCR Mycoplasma Detection Kit (Sigma, St. Louis, MO, USA). Knockdown cell lines were generated using the pLKO-Tet-On system. The pLKO-Tet-On plasmid for shRNA expression was obtained from Addgene (Cambridge, MA, USA) (Wiederschain et al., 2009), and shRNA sequences that target PRMT5 #1 (5′-CCACCTCCTTTCTATTAAG-3′: referring to #1832) (Deng et al., 2017), PRMT5 #2 (5′-GCCAGTTTGAGATGCCTTAT-3′: referring to #1577) (Deng et al., 2017), SC (5′-CACAAGATGAGACGACCAA-3′), MEP50 (5′-CCTCACAAGGACTCTGTGTTT-3′), and plCln (5′-CCAAAGATGAGACGACCAA-3′) were used for the construction of plasmids for stable cell line generation as described previously (Deng et al., 2017; Hsu and Hu, 2013). Lentiviral stably infected pools with Dox-inducible expression of PRMT5-targeting shRNA (shPRMT5 #2: referring to #1577 (Deng et al., 2017)) (LNCaP-shPRMT5 pool, PC3-shPRMT5 pool, and DU145-shRNA pool) were established and used for clonogenic assays. Stable cell lines with Dox-inducible expression of PRMT5-targeting shRNA (LNCaP-shPRMT5: referring to #1832 (Deng et al., 2017), LNCaP-shPRMT5 #2: referring to #1577 (Deng et al., 2017)) or scramble control-targeting shRNA (shSC) (LNCaP-shSC, PC3-shSC, and DU145-shSC) were established from individual clones and characterized previously (Deng et al., 2017). Stable cell lines with Dox-inducible expression of MEP50-targeting shRNA or plCln-targeting shRNA (LNCaP-shMEP50 and LNCaP-shplCln) were established from individual clones and characterized in this study.

**Dox-induced knockdown and inhibitor treatment conditions.** For Dox-inducible cell lines, Dox was applied at the final concentration of 1 μg/mL every 48 h to establish and maintain PRMT5 knockdown (shPRMT5), MEP50 knockdown (shMEP50), plCln knockdown (shplCln), or express scramble control shRNA (shSC). The number of days of Dox treatment was optimized: shPRMT5 and shSC cells were grown for 4 days and had 4 days of Dox treatment, shMEP50 were grown for 4 days and had 2 days of growth followed by 2 days of Dox treatment, and shplCln cells were grown for 5 days and had 5 days of Dox treatment. For parental cell lines, cells were treated with the PRMT5 inhibitor BLL3.3 (10 μM) or an equal volume of DMSO (control) every 48 h beginning 24 h after plating to inhibit PRMT5 activity. For IR experiments, cells were subjected to IR following the knockdown or inhibitor treatment described above.

**Ionizing radiation conditions.** For clonogenic assays, cells were irradiated using the GC-220 device (Atomic Energy of Canada, Ottawa, Canada) with a Co-60 radiation source as described previously (Deng et al., 2008, 2011). For all other experiments, cells were irradiated using the X-RAD 320 biological irradiation device (PXi Precision X-Ray, North Branford, CT, USA) with an x-ray tube radiation source at an average dose rate of ~1 Gy/25 sec. All IR treatments were carried out in normal air at room temperature, and cells spent minimal time outside incubators during treatment. Non-irradiated controls were mock-irradiated by being taken out of the incubator for the same time period as irradiated counterparts.

**Clonogenic assays.** Clonogenic assays to quantify the surviving fraction following IR was performed similar to previously reported (Deng et al., 2008, 2011). For Dox-inducible cell lines, Dox was applied at the final concentration of 1 μg/mL every 48 h to establish and maintain PRMT5 knockdown (shPRMT5) or express scramble control shRNA (shSC). Additionally, LNCaP cells were treated with the PRMT5 inhibitor BLL3.3 (10 μM) or an equal volume of dimethyl sulfoxide (DMSO) (control) every 48 hours beginning 24 hours after plating to inhibit PRMT5 activity. After 4 days, when cells reached ~80% confluency, cells were subjected to the indicated dose of IR and immediately harvested, collected, counted, and reseeded on fresh 6 well plates for clonogenic assay. After 14 days of growth, the number of colonies were counted to calculate the surviving fraction. The number of cells for reseeding was optimized based upon how much cell death was observed: (LNCaP: 0 Gy-500 cells, 2 Gy-700 cells, 4 Gy-1000 cells, 6 Gy-5000 cells, and 8 Gy-10000 cells), (PC3: 0 Gy-50 cells, 2 Gy-100 cells, 4 Gy-200 cells, 6 Gy-600 cells, and 8 Gy-1000 cells), (DU145: 0 Gy-50 cells, 2 Gy-100 cells, 4 Gy-200 cells, 6 Gy-400 cells, and 8 Gy-800 cells).
Immunocytochemistry (ICC) for quantification of IR-induced DSBs (Kuo and Yang, 2008), NHEJ-associated foci (Rapp, 2004; Slupianek et al., 2006), and HR-associated foci (Rapp, 2004; Slupianek et al., 2006). Cells were seeded on 6 cm dishes containing glass coverslips and treated as described elsewhere. When cells reached ~80% confluency, cells were treated with 2 Gy IR and then fixed with 3.7% formaldehyde in phosphate buffered saline (PBS) at room temperature for 20 minutes at the indicated time points: First, we assessed the formation and repair of DSBs by analyzing γ-H2AX foci in a time course following radiation (5 m and 1, 2, 6, and 24 h). Given that the majority of DSBs are repaired within 2-6 h following IR, we assessed the effect of knockdown or inhibitor on the repair of DSBs at the 6 and 24 h timepoints. To assess potential impact on HR or NHEJ, we assessed RAD51 and Ku70 foci, respectively, at 1 h following IR treatment which is when the majority of repair occurred. After fixation at the indicated timepoints, cells were permeabilized with 0.2% Triton X-100 in PBS at room temperature for 5 m. Cells were then blocked with 5% milk blocking solution in PBS, stained with the indicated primary antibodies diluted in 5% milk blocking solution in PBS, and stained with 4,6-diamidino-2-phenylindole (DAPI) final 10 µg/mL and indicated secondary antibodies diluted in 5% milk blocking solution in PBS. Cells on coverslips were mounted on glass slides using the ProLong® Antifade Kit (Invitrogen Molecular Probes, Eugene, OR, USA) and sealed with clear nail polish. Cells were then imaged via the Nikon TE2000 inverted fluorescence microscope under oil immersion (60x objective) (Nikon Instruments Melville, NY, USA). The number of foci was manually recorded for each cell (defined via nuclear DAPI staining). At least 60 cells were counted for each biological replicate. The arrays of foci counts for each biological replicate were subjected to further analysis separately to determine the average number of foci per cell and percentage of cells with zero foci. The primary antibodies used were anti-PRMT5-rabbit (1:1000), -γ-H2AX-mouse (1:1000), -γ-H2AX-rabbit (1:200), -AR-mouse (1:1000), -AR-rabbit (1:100), -RAD51-rabbit (1:1000), -Ku70-mouse (1:500), -MEP50-rabbit (1:100), -pICln-rabbit (1:1000), and -RuvBL1-rabbit (1:100). Secondary antibodies used were anti-mouse-FITC (1:100) and anti-rabbit-rhodamine red (1:1000). All antibodies are described in Table S6.

Immunocytochemistry (ICC) for quantification of protein expression or subcellular localization. Immunocytochemistry was performed as described above. Images were analyzed via Imagej (Schneider et al., 2012). First, the background was subtracted from the image using the rolling ball method (http://imagej.net/plugins/rolling-ball.html). For PRMT5 expression, regions of interest (ROI) were outlined for each individual cell. For AR expression, ROI were outlined for each nucleus (as defined by DAPI staining). For MEP50 and pICln expression and subcellular localization, ROI were outlined for each individual cell, nucleus only (as defined by DAPI staining), and cytoplasm only (as defined by signal outside of DAPI staining). The average intensity for each ROI was measured and at least 60 cells were counted for each biological replicate. The arrays of intensity counts for each biological replicate were subjected to further analysis separately and were analyzed via both “D’Agostino & Pearson” and “Shapiro-Wilk” normality tests to evaluate distribution. Because not all samples were normally distributed, the median value was used for each biological replicate. To determine the nuclear:cytoplasmic ratio (N:C) the value for nucleus was divided by the value for cytoplasmic for each cell individually such that an N:C ratio of 1 indicates equal expression in both the nucleus and cytoplasm.

Comet assay. To determine if PRMT5 regulates the repair of IR-induced DSBs, we used comet assay to quantify DNA damage directly. LNCaP-shPRMT5 cells were seeded on 6 cm dishes and Dox was applied at the final concentration of 1 µg/mL every 48 h to establish and maintain PRMT5 knockdown. After 4 days, when cells reached ~80% confluency, cells were treated with the indicated dose of IR and then harvested and counted after either 5 m or 2 h. The 5 m timepoint indicates how much total DNA damage is induced by radiation. Comparing the 2 h timepoint to the 5 m timepoint indicates how much DNA damage is repaired. Twenty thousand cells per group were diluted in 100 µL of 0.5% Low Melting Agarose in PBS at 45°C and 50 µL of diluted cells were immobilized onto pretreated VWR Superfrost Plus slides (previously dipped in 1% Agarose in nanopure water and allowed to dry overnight). Glass coverslips were placed on top of the cell dilution and the slides were placed in 4°C for 10 minutes to solidify the agarose. Slides were moved to room temperature for 5 minutes, the coverslips removed, and immobilized cells were lysed in 4°C neutral lysis buffer (10 mM Tris HCl pH 8.0, 100 mM EDTA, 2.5 M NaCl, 1% Sarkosyl, 0.5% Triton X-100) for 60 minutes at 4°C. Slides were removed from lysis buffer and equilibrated in Neutral Comet Electrophoresis Buffer (90 mM Tris HCl pH 8.0, 90 mM Boric Acid, 2 mM EDTA) for 20 minutes. Electrophoresis was performed at 14V, 27mA for 60 minutes. After electrophoresis, slides were equilibrated in 0.4 M Tris-HCl pH 7.4 for 5 minutes at room temperature. The equilibration buffer was replaced with fresh buffer, and the slides were incubated for an additional 5 minutes. This wash was repeated one additional time for a total of three washes. Sixty µL of DAPI (0.5 µg/mL in H2O) was applied dropwise to the agarose pad, and slides were incubated at 4°C for 15 minutes. Comets were then imaged via the Nikon TE2000 inverted fluorescence microscope (20x objective) (Nikon Instruments Melville, NY, USA) and analyzed with Imagej (Schneider et al., 2012). To quantify the % tail DNA’ in each cell from the images, we utilized the comet assay plugin created by Robert Bagnell (2011) based on the NIH Image comet assay by Herbert M. Miller (1997). At least 65 thousand cells were analyzed across 3 biological replicates and the ‘% tail DNA’ values were pooled for statistical analysis via Mann-Whitney U-test. Although several reports using comet assay have used various data representation and statistical analysis (Higo et al., 2017; Lee et al., 2017; Mo et al., 2018; Nassour et al., 2016), because of the high variance within each biological replicate and lack of normal distribution we used the Mann-Whitney U-test (Dungrawala et al., 2017; Liu et al., 2018; Xiao et al., 2018).
Etoposide treatment. To assess if PRMT5 is required for repair of DSBs in general, we used etoposide to induce replication-dependent DSBs. LNCaP-shPRMT5 cells were seeded on 6 cm dishes containing glass coverslips and Dox was applied at the final concentration of 1 µg/mL every 48 h to establish and maintain PRMT5 knockdown. When cells reached ~60% confluency, cells were treated with either etoposide (10 µM) or an equal volume of DMSO. Forty-eight h after initiation of treatment, coverslips were transferred to a new dish and subjected to γH2AX-foci analysis described above while the remaining cells were harvested and subjected to western blot analysis. Although not shown, experiments with short etoposide treatments (2 h, 6 h) were unsuccessful and the 48 h etoposide treatment time was likely optimal because cells could undergo DNA replication which induced DSBs.

Transient transfection for rescue of AR expression. To evaluate if the role of PRMT5 in the repair of IR-induced DSBs is independent of AR, LNCaP-shPRMT5 cells were seeded on 6 cm dishes containing glass coverslips and Dox was applied at the final concentration of 1 µg/mL every 48 h to establish and maintain PRMT5 knockdown. Forty-eight h following seeding, cells were transfected with pCMV-Flag2-AR, as described previously (Deng et al., 2017; Hsu and Hu, 2013), or pCMV-Empty Vector plasmid using FuGENE HD (Promega, Madison, Wisconsin, USA). pCMV-HA-CFP was used as a transfection control. Upon reaching ~80% confluency (48 h following transfection), cells were treated with 2 Gy IR and subjected to immunocytochemistry analysis. Only transfected cells (CFP+) were subjected to γH2AX foci analysis, while both transfected and non-transfected cells were subjected to protein expression analysis as described above. For the microscope images, we used 3D representation to show the expression of multiple proteins in a single cell at the same time. Each peak is a cell and the height of each peak is the intensity of signal.

RNA-seq for identification of PRMT5 target genes in response to IR. LNCaP-shPRMT5 cells were seeded on 6 cm dishes and Dox was applied at the final concentration of 1 µg/mL every 48 h to establish and maintain PRMT5 knockdown for 4 days. Cells were harvested 1 h following a 2 Gy IR treatment and total RNA was isolated using Trizol Reagent (Ambion, Carlsbad, CA, USA). PolyA+ RNA libraries were generated according to the Illumina “TruSeq Stranded mRNA Sample Preparation Guide” (15031047E) with the following considerations: (1) an Agilent Bioanalyzer RNA-Nano kit was used to assess RNA concentration and rule out sample degradation. (2) Heat and divalent cation fragmentation of the polyA+ RNA was undertaken for 4 m rather than the default of 8 m. (3) The number of PCR cycles for library amplification was determined by the yield of cDNA. For both RNA-seq analyses, we ran 8 cycles of PCR instead of the 15 cycles mentioned in the manual. (4) Final cleanup was performed using a 0.8:1 bead:sample ratio with AmPure XP beads instead of the 1:1 mentioned in the manual. IR+ group was run on an Illumina HiSeq 2500 using High Output flowcell to produce paired-end 101 base reads. IR- group was run on an Illumina NovaSeq 6000 S4 flowcell that generated paired-end 151 base reads. Additionally, IR- samples were prepared and run with unique dual indexes to mitigate potential "index-hopping" associated with Illumina instruments using "exclusion amplification" clustering on patterned flowcells.

RNA-seq quality was assessed by FastQC, and STAR RNA-seq aligner (Dobin et al., 2013) was used to map all high-quality sequences to the human genome (GENCODE GRCh38). Read counts were evaluated using Subread featureCounts (Liao et al., 2014) to summarize uniquely mapped reads to the gene level according to the GENCODE M25 annotation file. Data was normalized by trimmed mean of M value method to obtain the final profile of gene expression (base-2 log scale). EdgeR (Robinson et al., 2010) was used to perform differential expression analysis by comparing Dox+ (PRMT5 KD) and Dox- (no KD) for IR+ and IR- groups. After removing low-expressed genes (average expression levels lower than 1 for both conditions), we defined genes as differentially expressed genes (DEGs) if their FDR-adjusted p-values were less than 0.01, and the magnitudes of fold-changes (FCs) were larger than log2 (1.25).

Gene Ontology (GO) and pathway analysis were performed on the ‘IR+ only’ DEGs. GO analysis was performed using the web-based tool DAVID functional annotation analysis (http://david.abcc.ncifcrf.gov/home.jsp v6.8) (Huang et al., 2007, 2009). Only GO annotations with FDR-adjusted p-values less than 0.05 and the fold enrichment score larger than 1.5 were selected as significantly over-represented GO terms. Pathway analysis on IR+ only DEGs was performed using Ingenuity Pathway Analysis (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis) to identify differentially regulated pathways upon PRMT5 knockdown in irradiated cells.

RNA isolation, reverse transcription, and RT-qPCR. Cells were seeded on either 6 cm or 10 cm dishes and treated as described elsewhere. Total RNA was isolated using Trizol Reagent (Ambion, Carlsbad, CA, USA). RNA concentration and integrity were verified by agarose gel electrophoresis. cDNA synthesis was done using High Capacity cDNA Reverse Transcription Kit (Promega, Madison, WI, USA) as described previously (Deng et al., 2017; Hsu and Hu, 2013; Zhang et al., 2014). qPCR was performed using FastStart Universal SYBR Green Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) on the QuantStudio 6 Flex System and QuantStudio™ Real-Time PCR Software (ThermoFisher, Waltham, MA, USA). Forty cycles were run and samples without Ct values were deemed undetected. Technical duplicates were run for each sample and the Ct values used for further analysis were the average of the technical duplicates. Samples where Ct values for technical duplicates were >0.5 apart were re-run. Non-template controls (NTCs) with autoclaved double-distilled H2O were also run for each primer set and primer sets where Ct values for NTC were lower than 37 (indicating high background) were re-run. Amplicon size and specificity were verified for each primer set via agarose gel electrophoresis. PRMT5, AR, and GAPDH primers were used previously (Deng et al., 2017; Zhang et al., 2014). IVL primers were used previously (Chew et al., 2013; Saha et al., 2016). All primers used are described in Table S7.
**Chromatin immunoprecipitation (ChIP)-qPCR assay.** LNCaP-shPRMT5 or LNCaP-shSC cells were seeded on multiple 10 cm dishes and Dox was applied at the final concentration of 1 μg/mL every 48 h to establish and maintain PRMT5 knockdown (shPRMT5) or express scramble control shRNA (shSC). After 4 days, when cells reached ~80% confluency, cells were treated with 2 Gy IR. One hour following IR (prior to the repair of the majority of DSBs and at the same time as the peak of IR-induced PRMT5 protein expression), cells were fixed/crosslinked and chromatin was prepared for ChIP-qPCR as described previously (Deng et al., 2017). Chromatin fragments were verified to be ~500 base pairs by agarose gel electrophoresis. Antibodies used for immunoprecipitation were anti-PRMT5-rabbit, -H4R3me2s-rabbit, -H3K9ac-rabbit, -H3R2me2s-rabbit, -H3R8me2s-rabbit, -H2AR3me2s-rabbit, -MEP50-rabbit, -pCln-rabbit, and IgG-rabbit. All antibodies are described in Table S6. Primers used for ChIP-qPCR are described in Table S7.

**Flow cytometry cell-cycle analysis.** LNCaP-shPRMT5 cells were seeded on 6 cm dishes and Dox was applied at the final concentration of 1 μg/mL every 48 h to establish and maintain PRMT5 knockdown. After 4 days, when cells reached ~80% confluency, IR+ cells were treated with 2 Gy IR. Cells were harvested 24 h following IR, resuspended in PBS, and filtered through a 70 μm nylon cell strainer to remove all cell aggregates. A single cell suspension was prepared and verified via microscopy. Cells were then fixed in 70% ethanol, stained with a Propidium Iodide (PI) containing solution (20 μg/mL PI and RNaseA diluted in PBS) and subjected to flow cytometry analysis via the Guava EasyCyte Flow Cytometer (Guava Technologies, Hayward, CA, USA). At least 20,000 live cells were counted for each biological replicate. Flow cytometry data was analyzed via FlowJo (FlowJo, LLC, Ashland, Oregon, USA). Live cells were gated for analysis to remove any sub-G1 cells and then were subjected to cell cycle analysis via Dean-Jett-Fox modeling (Fox, 1980).

**Western blot.** Cells were seeded on either 6 cm or 10 cm dishes and treated as described elsewhere. Cells were harvested in lysis buffer (100 mM Tris-HCl pH 8.0, 15 mM MgCl₂, 100 mM KCl, 5 μg/mL of each Chymostatin, Leupeptin, Pepstatin A, and antipain in DMSO, 1% Triton X-100, 1 mM PMSF in ethanol, and 1 mM DTT) or RIPA buffer (10 mM Tris-HCl pH 8.0, 5 mM EDTA, 1% Triton X-100, 0.1% Sodium Deoxycholate, 0.1% SDS, 140 mM NaCl, 5 μg/mL of each Chymostatin, Leupeptin, Pepstatin A, and antipain in DMSO, and 1 mM PMSF in ethanol) and total protein concentration was measured using Bradford method. Approximately 20-30 μg total protein was run on a 10-15% SDS-PAGE and western blotting was performed as described previously (Deng et al., 2017; Hsu and Hu, 2013; Zhang et al., 2014). Band/protein intensity was quantified using Image Lab™ (Bio-rad, Hercules, CA, USA). Antibodies used for western blot were anti-PRMT5-rabbit (1:1000), -AR-rabbit (1:2000), -γH2AX-rabbit (1:1000), -RAD51-rabbit (1:2000), -RAD51D-rabbit (1:2000), -RAD51AP1-rabbit (1:1000), -NHEJ1-rabbit (1:2000), -β-Actin-mouse (1:2000), -MEP50-rabbit (1:500), -pCln-rabbit (1:2000), -RuvBL1-rabbit (1:1000), -Tip60-rabbit (1:500), -rabbit-HRP (horseradish peroxidase) (1:1000), -mouse-HRP (1:1000). All antibodies are described in Table S6.

**Bimolecular Fluorescence Complementation (BIFC) assay.** LNCaP cells were grown to ~60% confluency and transfected with plasmids to visualize the PRMT5:MEP50 interaction (pMYC-VN155-PRMT5, pHA-VC-MEP50, and pFlag-NLS-CFP) and PRMT5:pCln interaction (pMYC-VN155-PRMT5, pHA-VC-pCln, and pFlag-NLS-CFP). Forty-eight hours following transfection, cells were treated with 2 Gy IR. Immediately prior to IR and 6 h following IR (the time point with the largest changes in MEP50 and pCln subcellular localization), cells were imaged via the Nikon TE2000 inverted fluorescence microscope (20x objective) (Nikon Instruments Melville, NY, USA). Images were then analyzed with ImageJ (Schneider et al., 2012). First, the background was subtracted from the image using the rolling ball method (http://imagej.net/plugins/rolling-ball.html). ROI were outlined for each individual cell, nucleus only (as defined by NLS-CFP staining), and cytoplasm only (as defined by staining outside NLS-CFP signal). The average intensity for each ROI was measured and at least 50 cells were counted for each biological replicate. The arrays of intensity counts for each biological replicate were subjected to further analysis separately and were analyzed via both “D’Agostino & Pearson” and “Shapiro-Wilk” normality tests to evaluate distribution. Because not all samples were normally distributed, the median value was used for each biological replicate. To determine the nuclear:cytoplasmic ratio (N:C) the value for nucleus was divided by the value for cytoplasmic for each cell individually such that an N:C ratio of 1 indicates equal protein-protein interaction in both the nucleus and cytoplasm.

**Transient knockdown of RuvBL1 and Tip60.** To confirm that the mechanism we describe here is independent of PRMT5-mediated regulation of RuvBL1 and Tip60, we performed similar assays with knockdown of RuvBL1 or Tip60. First, we obtained MISSION® shRNA bacterial glycerol stocks containing shRNA expression plasmids (RuvBL1: TRCN0000018911, TRCN0000018912, TRCN0000001893, TRCN0000001894, and TRCN0000319216. Tip60: TRCN0000020314, TRCN0000020315, TRCN0000020317, TRCN0000020318, and TRCN0000298504) (Sigma-Aldrich/Millipore Sigma, St. Louis, Missouri, USA). Using maxiprep, we isolated the shRNA expression plasmids and generated viral particles in HEK293T cells as described previously (Hsu and Hu, 2013) via co-transfection of all 5 shRuvBL1 or all 5 shTip60 expression plasmids along with pCMV-HA-CFP as a control. Although we could have used transient transfection of individual shRNA expression plasmids, we used viral particle transduction with all 5 shRNA expression vectors at once to ensure sufficient knockdown. FuGENE HD (Promega, Madison, Wisconsin, USA) was used as the transfection reagent, pHR'-CMV-8.2∆VPR was used as the packaging plasmid, and pHR'-CMV-VSV-G was used as the envelope plasmid. Forty-eight hours following transfection, media from the HEK293T cells was collected, passed through a 0.45 μm filter, and applied to the LNCaP cells for viral particle transduction. Viral particles were applied to the LNCaP cells both 24 hours and 72 hours after plating.
LNCaP cells were transduced with either shRuvBL1 or shTip60 viral particles once and again after 48 h to establish RuvBL1 or Tip60 knockdown. Cells were then treated with 2 Gy IR and subjected to γH2AX-foci analysis and western blot analysis described above.

**Correlation analysis of TCGA clinical cancer data sets.** Gene expression profiles of 32 clinical cancer data sets from TCGA Pan-Cancer analysis (The Cancer Genome Atlas Research Network et al., 2013) were retrieved from cBioPortal (Cerami et al., 2012; Gao et al., 2013). Using the mRNA expression of PRMT5, pICln, MEP50, AR, and DDR genes which are primary target genes of both PRMT5 and AR, we calculated the Spearman correlations between gene pairs for each cancer type. The gene set for DDR genes was defined as RAD51, RAD51D, RAD51AP1, NHEJ1, BRCA1, BRCA2, WE1, DNAPKcs, Ku70, Ku80, an XRCC4. Although we did not perform additional studies on Ku70, Ku70 was included as it is another well-studied, key regulator of NHEJ. In Figure 7D, a cutoff of p < 0.01 was used to determine the significance of correlation between PRMT5 and AR as either positive, negative, or no correlation if p > 0.01, in order to stratify the cancers into the different types.

**Statistical analysis.** No statistical methods were used to predetermine sample size. For the correlation analysis of TCGA clinical cancer data sets, statistical analysis was performed using Wilcoxon rank sum test in R 3.5.3. (R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, https://www.R-project.org/). All other statistical analyses were performed using Graphpad Prism 7.00 and 8.00 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com). Statistical analysis for comet assay and RNA-seq analysis are described above. For all other experiments, statistical analysis was performed on raw data with assumed normal distribution. For all qPCR experiments, statistical analysis was performed on ΔC\textsubscript{T} values (C\textsubscript{T} value of gene normalized to C\textsubscript{T} value of GAPDH control). For all ChIP-qPCR experiments, statistical analysis was performed on ΔC\textsubscript{T} values (C\textsubscript{T} value of gene normalized to C\textsubscript{T} value of IgG control). For all western blot experiments, statistical analysis was performed on normalized raw intensity values (intensity value of protein divided by the intensity value of β-Actin). When comparing two sample groups, we used unpaired, two-tailed t-tests with Welch’s correction (Welch’s t-test) because standard deviations were not always equal for all groups. When comparing multiple sample groups, in order to compare the means or medians among all the samples and incorporate the standard deviation of each of the samples, Brown-Forsythe and Welch ANOVA followed by Dunnett’s T3 multiple comparisons test was used. For Figures 1A, 1B, 1D, and 1E, as the variance in the mean among samples were small and the dose-response occurred on a log scale, statistical analysis was performed using Welch’s t-test of log-transformed data. All relevant statistics are reported in the corresponding legends.
SUPPLEMENTAL REFERENCES

Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2, 401–404.

Chew, Y.C., Adhikary, G., Xu, W., Wilson, G.M., and Eckert, R.L. (2013). Protein Kinase C δ increases Kruppel-like Factor 4 Protein, which Drives Involucrin Gene Transcription in Differentiating Keratinocytes. J. Biol. Chem. 288, 17759–17768.

Deng, X., Liu, H., Huang, J., Cheng, L., Keller, E.T., Parsons, S.J., and Hu, C.-D. (2008). Ionizing Radiation Induces Prostate Cancer Neuroendocrine Differentiation through Interplay of CREB and ATF2: Implications for Disease Progression. Cancer Res. 68, 9663–9670.

Deng, X., Elzey, B.D., Poulsen, J.M., Morrison, W.B., Ko, S.-C., Hahn, N.M., Ratliff, T.L., and Hu, C.-D. (2011). Ionizing radiation induces neuroendocrine differentiation of prostate cancer cells in vitro, in vivo and in prostate cancer patients. Am J Cancer Res 1, 834–844.

Deng, X., Shao, G., Zhang, H.T., Li, C., Zhang, D., Cheng, L., Elzey, B.D., Pill, R., Ratliff, T.L., Huang, J., et al. (2017). Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene 36, 1223–1231.

Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21.

Dungerwala, H., Bhat, K.P., Le Meur, R., Chazin, W.J., Ding, X., Sharan, S.K., Wessel, S.R., Sathe, A.A., Zhao, R., and Cortez, D. (2017). RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks. Mol. Cell 67, 374-386.e5.

Fox, M.H. (1980). A model for the computer analysis of synchronous DNA distributions obtained by flow cytometry. Cytometry A 1, 71–77.

Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, 1–34.

Higo, T., Naito, A.T., Sumida, T., Shibamoto, M., Okada, K., Nomura, S., Nakagawa, A., Yagamuchi, T., Sakai, T., Hashimoto, A., et al. (2017). DNA single-strand break-induced DNA damage response causes heart failure. Nat. Commun. 8, 15104.

Hsu, C.-C., and Hu, C.-D. (2013). Transcriptional activity of c-Jun is critical for the suppression of AR function. Mol. Cell. Endocrinol. 372, 12–22.

Huang, D.W., Sherman, B.T., Tan, Q., Collins, J.R., Alwood, W.G., Roaeyai, J., Stephens, R., Baseler, M.W., Lane, H.C., and Lempicki, R.A. (2007). The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8, R183.

Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44–57.

Kuo, L.J., and Yang, L.-X. (2008). γ-H2AX-a novel biomarker for DNA double-strand breaks. In Vivo 22, 305–309.

Lee, J.-H., Park, S.-J., Hariharasudhan, G., Kim, M.-J., Jung, S.M., Jeong, S.-Y., Chang, I.-Y., Kim, C., Kim, E., Yu, J., et al. (2017). ID3 regulates the MDC1-mediated DNA damage response in order to maintain genome stability. Nat. Commun. 8, 903.

Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930.

Liu, H., Zhang, H., Wu, X., Ma, D., Wu, J., Wang, L., Jiang, Y., Fei, Y., Zhu, C., Tan, R., et al. (2018). Nuclear cGAS suppresses DNA repair and promotes tumorigenesis. Nature 563, 131–136.

Mo, L.-J., Song, M., Huang, Q.-H., Guan, H., Liu, X.-D., Xie, D.-F., Huang, B., Huang, R.-X., and Zhou, P.-K. (2018). Exosome-packaged miR-1246 contributes to bystander DNA damage by targeting LIG4. Br. J. Cancer 119, 492–502.

Nassour, J., Martien, S., Martin, N., Deruy, E., Tomellini, E., Malaquin, N., Bouafi, F., Sabatier, L., Wernert, N., Pinte, S., et al. (2016). Defective DNA single-strand break repair is responsible for senescence and neoplastic escape of epithelial cells. Nat. Commun. 7, 10399.

Rapp, A. (2004). After double-strand break induction by UV-A, homologous recombination and nonhomologous end joining cooperate at the same DSB if both systems are available. J. Cell Sci. 117, 4935–4945.

Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140.

Saha, K., Adhikary, G., and Eckert, R.L. (2016). MEP50/PRMT5 Reduces Gene Expression by Histone Arginine Methylation and this is Reversed by PKCδ/p38δ Signaling. J. Invest. Dermatol. 136, 214–224.

Schneider, C.A., Rasband, W.S., Eliceiri, K.W., and others (2012). NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671–675.

Slupianek, A., Nowicki, M.O., Kopytka, M., and Skorski, T. (2006). BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair 5, 243–250.

The Cancer Genome Atlas Research Network, Weinstein, J.N., Collins, E.A., Mills, G.B., Shaw, K.R.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013). The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120.

Wiederschain, D., Susan, W., Chen, L., Loo, A., Yang, G., Huang, A., Chen, Y., Caponigro, G., Yao, Y., Lengauer, C., et al. (2009). Single-vector inducible lentiviral RNAi system for oncology target validation. Cell Cycle 8, 498–504.

Xiao, X., Liang, J., Huang, C., Li, K., Xing, F., Zhu, W., Lin, Z., Xu, W., Wu, G., Zhang, J., et al. (2018). DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage. Nat. Commun. 9.